

## COMBINATION CHEMOTHERAPY

5 This application is a continuation application of USSN 09/869,030 filed October 18, 2001 which is a 371 application of PCT/US99/30485 filed December 21, 1999, which claims the benefit of priority to United States provisional application Serial No. 60/113,291 filed December 22, 1998 and United States provisional application Serial No. 60/164,788 filed November 10, 1999.

## FIELD OF THE INVENTION

10 This invention relates to a method for treating cancer in a patient in need of such treatment, said method comprising the step of administering to the patient a mitotic inhibitor and the step of administering to the patient a MEK inhibitor. The invention also relates to compositions or packaged units comprising a mitotic inhibitor and a MEK inhibitor.

## BACKGROUND OF THE INVENTION

15 Cancer chemotherapy can entail the use of a combination of agents, generally as a means to reduce the toxic effects of the individual agents when used alone, and in some instances because the combination has greater efficacy than when either agent is used alone.

20 Mitotic inhibitors are antineoplastic agents that adversely affect the microtubular network in cells that is essential for mitotic and interphase cellular function. Mitotic inhibitors generally bind to free tubulin in cells, promoting the assembly of tubulin into stable microtubules, and simultaneously inhibiting their disassembly. Thus stabilized, microtubules cannot function normally, which in turn results in the inhibition of interphase and mitotic functions in the cell.

25 Several mitotic inhibitors are now used clinically to treat a variety of cancers. For example, paclitaxel, a natural product, is an antimicrotubule agent that not only promotes the assembly of microtubules from tubulin dimers but also stabilizes microtubules by preventing depolymerization. In addition, paclitaxel

induces abnormal arrays or bundles of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis. Paclitaxel is indicated primarily for ovarian carcinoma and breast cancer, although it is useful in treating other cancers such as lung cancer. Use of paclitaxel is generally accompanied by undesirable side effects, including hypersensitivity reactions, hypotension, bradycardia, hypertension, nausea and vomiting, and injection-site reactions. Docetaxel, another mitotic inhibitor, acts much like paclitaxel in its ability to bind to microtubules. Other mitotic inhibitors include the vinca alkaloids, such as vinblastine, vincristine and vinorelbine, as well as derivatives of such compounds such as vinflunine.

MEK inhibitors are compounds which inhibit one or more of the family of mammalian enzymes known as MAP kinase kinases, which phosphorylate the MAP kinase subfamily of enzymes (mitogen-associated protein kinase enzymes) referred to as MAP kinases or ERKs (extracellular signal-regulating enzymes such as ERK1 and ERK 2). These enzymes regulate phosphorylation of other enzymes and proteins within the mammalian body. MEK 1 and MEK 2, as well as ERK1 and ERK 2, are dual specificity kinases that are present in all cell types and play a critical role in the regulation of cell proliferation and differentiation in response to mitogens and a wide variety of growth factors and cytokines. Upon activation, these enzymes control a cascade that can phosphorylate a large number of substrates, including transcription factors, the EGF receptor, phospholipase A2, tyrosine hydroxylase, and cytoskeletal proteins. One selective MEK inhibitor has been shown to be useful to treat a number of proliferative disorders, including psoriasis, restenosis, and cancer, as described in US Patent No. 5,525,625, incorporated herein by reference. A whole series of MEK inhibitors have been described as useful to prevent and treat septic shock, see WO 98/37881.

The prior art fails to teach or suggest that any such selective MEK inhibitors can be combined with mitotic inhibitors according to this invention.

## SUMMARY OF THE INVENTION


This invention features a method for treating a proliferative disease, said method including (a) the step of administering to a patient in need of such treatment a MEK inhibitor and (b) the step of administering to said patient a mitotic inhibitor, wherein the amount of the MEK inhibitor and the amount of the mitotic inhibitor are such that the combination of the agents is an effective anti-proliferative therapy. The administration of a mitotic inhibitor may be before, during, or after the administration of the MEK inhibitor. Simultaneous administration may be by the same (both actives by either local or systemic injection) or different routes (e.g., oral administration of a MEK inhibitor and intravenous administration of the mitotic inhibitor). The invention also encompasses the use of additional pharmaceutical agents, such as a second MEK inhibitor, an inhibitor of farnesyl transferase (a ras inhibitor), a RAF inhibitor, a second mitotic inhibitor, an anti-angiogenesis agent, a steroid, or other anti-cancer agents, as well as adjuvants, enhancers, or other pharmaceutically active and pharmaceutically acceptable materials. Therefore, the invention provides a method for treating cancer by administering at least one (e.g., one, two, or three) MEK inhibitors and at least one (e.g., one or two) mitotic inhibitors to the patient. In one aspect, the amounts of each active may vary independently from each other over time. For example, a patient may receive a first MEK inhibitor with a mitotic agent for a period of time, and then the first MEK inhibitor may be replaced by a second MEK inhibitor.

The invention also features compositions, packaged units, and kits which include at least one MEK inhibitor and at least one mitotic inhibitor. For example, the invention encompasses: (a) a single formulation (whether tablet, solution, or suspension, for example) that includes both a mitotic inhibitor and a MEK inhibitor; (b) a blister pack containing separate formulations of each active, such as a tablet or capsule form of a MEK inhibitor and a capsule or ampoule of a solution of a mitotic inhibitor; and (c) a kit with separate formulations of each active packaged together in a box with instructions for combination administration.

Selective MEK 1 or MEK 2 inhibitors are those compounds which inhibit the MEK 1 or MEK 2 enzymes without substantially inhibiting other enzymes such as MKK3, ERK, PKC, Cdk2A, phosphorylase kinase, EGF and PDGF receptor kinases, and C-src. In general, a selective MEK 1 or MEK 2 inhibitor has an  $IC_{50}$  for MEK 1 or MEK 2 that is at least one-fiftieth (1/50) that of its  $IC_{50}$  for one of the above-named other enzymes. Preferably, a selective inhibitor has an  $IC_{50}$  that is at least 1/100, more preferably 1/500, and even more preferably 1/1000, 1/5000 or less than that of its  $IC_{50}$  for one or more of the above-named enzymes.

In a preferred embodiment, the combination to be used according to this invention comprises the mitotic inhibitor paclitaxel. In another embodiment, a mitotic inhibitor is used in combination with the MEK inhibitor 2-(2-amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran, which is described in US Patent No. 5,525,625. In another preferred embodiment, the mitotic inhibitor administered is selected from paclitaxel, docetaxel, vincristine, vinblastine, vinorelbine, and vinflunine.

According to one aspect of the invention, the mitotic inhibitor is administered in combination with a selective MEK inhibitor which is a phenyl amine derivative of Formula I.



I

In Formula (I), R<sub>1</sub> is hydrogen, hydroxy, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> alkoxy, halo, trifluoromethyl, or CN. R<sub>2</sub> is hydrogen. R<sub>3</sub>, R<sub>4</sub>, and R<sub>5</sub> are independently selected from hydrogen, hydroxy, halo, trifluoromethyl, C<sub>1</sub>-C<sub>8</sub> alkyl,

C<sub>1</sub>-C<sub>8</sub> alkoxy, nitro, CN, and -(O or NH)<sub>m</sub>-(CH<sub>2</sub>)<sub>n</sub>-R<sub>9</sub>. R<sub>9</sub> is hydrogen, hydroxy, COOH, or NR<sub>10</sub>R<sub>11</sub>; n is 0-4; m is 0 or 1.

Each of R<sub>10</sub> and R<sub>11</sub> is independently selected from hydrogen and C<sub>1</sub>-C<sub>8</sub> alkyl, or taken together with the nitrogen to which they are attached can complete a 3-10 member cyclic ring optionally containing 1, 2, or 3 additional heteroatoms selected from O, S, NH, or N-(C<sub>1</sub>-C<sub>8</sub> alkyl). Z is COOR<sub>7</sub>, tetrazolyl, CONR<sub>6</sub>R<sub>7</sub>, CONHNR<sub>10</sub>R<sub>11</sub>, or CH<sub>2</sub>OR<sub>7</sub>. R<sub>6</sub> and R<sub>7</sub> independently are hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, (CO)-C<sub>1</sub>-C<sub>8</sub> alkyl, aryl, heteroaryl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, or C<sub>3</sub>-C<sub>10</sub> (cycloalkyl optionally containing one, two, or three heteroatoms selected from O, S, NH, or N alkyl); or R<sub>6</sub> and R<sub>7</sub> together with the nitrogen to which they are attached complete a 3-10 member cyclic ring optionally containing 1, 2, or 3 additional heteroatoms selected from O, S, NH, or N alkyl. In formula (I), any of the foregoing alkyl, alkenyl, aryl, heteroaryl, heterocyclic, and alkynyl groups can be unsubstituted or substituted by halo, hydroxy, C<sub>1</sub>-C<sub>6</sub> alkoxy, amino, nitro, C<sub>1</sub>-C<sub>4</sub> alkylamino, di(C<sub>1</sub>-C<sub>4</sub>)alkylamino, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, phenyl, phenoxy, C<sub>3</sub>-C<sub>5</sub> heteroaryl or heterocyclic radical, or C<sub>3</sub>-C<sub>5</sub> heteroaryloxy or heterocyclic radical-oxy. The invention also provides a pharmaceutically acceptable salt, ester, amide, or prodrug of each of the disclosed MEK inhibitors.

Preferred embodiments of Formula (I) have a structure wherein: (a) R<sub>1</sub> is hydrogen, methyl, methoxy, fluoro, chloro, or bromo; (b) R<sub>2</sub> is hydrogen; (c) R<sub>3</sub>, R<sub>4</sub>, and R<sub>5</sub> independently are hydrogen, fluoro, chloro, bromo, iodo, methyl, methoxy, or nitro; (d) R<sub>10</sub> and R<sub>11</sub> independently are hydrogen or methyl; (e) Z is COOR<sub>7</sub>, tetrazolyl, CONR<sub>6</sub>R<sub>7</sub>, CONHNR<sub>10</sub>R<sub>11</sub>, or CH<sub>2</sub>OR<sub>7</sub>; R<sub>6</sub> and R<sub>7</sub> independently are hydrogen, C<sub>1-4</sub> alkyl, heteroaryl, or C<sub>3-5</sub> cycloalkyl optionally containing one or two heteroatoms selected from O, S, or NH; or R<sub>6</sub> and R<sub>7</sub> together with the nitrogen to which they are attached complete a 5-6 member cyclic ring optionally containing 1 or 2 additional heteroatoms selected from O, NH or N-alkyl; and wherein any of the foregoing alkyl or aryl groups can be unsubstituted or substituted by halo, hydroxy, methoxy, ethoxy, or heteroaryloxy (such as 2,3,4,5,6-pentafluorophenyl); (f) Z is COOR<sub>7</sub>; (g) R<sub>7</sub> is H, pentafluorophenyl, or tetrazolyl; (h) R<sub>3</sub>, R<sub>4</sub>, and R<sub>5</sub> are independently H, fluoro, or

chloro; (i)  $R_4$  is fluoro; (j) two of  $R_3$ ,  $R_4$ , and  $R_5$  are fluoro; (k) or combinations of the above. In another preferred embodiment of Formula (I),  $R_1$  is methyl, fluoro, chloro, or bromo.

5           In a more preferred embodiment, the MEK inhibitor is selected from a compound in Formula (I) Compound Table below.

FORMULA (I) COMPOUND TABLE  
(page 1 of 9)

	[4-Chloro-2-(1H-tetrazol-5-yl)-phenyl-(4-iodo-2-methyl-phenyl)-amine (4-iodo-2-methyl-phenyl)-[2-(1H-tetrazol-5-yl)-phenyl]amine
5	[4-nitro-2-(1H-tetrazol-5-yl)-phenyl-(4-iodo-2-methyl-phenyl)-amine 4-Fluoro-2-(4-iodo-2-methylphenylamino)benzoic acid 3,4,5-Trifluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid
10	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid Sodium 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-benzoate 5-Bromo-2-(4-iodo-2-methyl-phenylamino)-benzoic acid 2-(4-Iodo-2-methyl-phenylamino)-5-nitro-benzoic acid 4-Chloro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid
15	2-(4-Iodo-2-methyl-phenylamino)-benzoic acid 5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid 5-Iodo-2-(4-iodo-2-methyl-phenylamino)-benzoic acid 2,3,5-Trifluoro-4-(4-iodo-2-methyl-phenylamino)-benzoic acid 2-(4-Iodo-phenylamino)-5-methoxy-benzoic acid
20	5-Methyl-2-(4-iodo-2-methyl-phenylamino)-benzoic acid 2-(4-Iodo-2-methyl-phenylamino)-4-nitro-benzoic acid 2-(4-Bromo-2-methyl-phenylamino)-4-fluoro-benzoic acid 2-(2-Bromo-4-iodo-phenylamino)-5-nitro-benzoic acid 2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-benzoic acid
25	5-Chloro-N-(2-hydroxyethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-benzamide N-Ethyl-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N,N-dimethyl-benzamide
30	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(1H-tetrazol-5-yl)-benzamide 5-Bromo-2-(4-iodo-2-methyl-phenylamino)-benzamide 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N,N-dimethyl-benzamide

FORMULA (I) COMPOUND TABLE  
(page 2 of 9)

	[5-Chloro-2-(4-iodo-2-methyl-phenylamino)-benzoylamino]-acetic acid
	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-propyl-benzamide
5	5-Bromo-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide
	N,N-Diethyl-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide
	4-Fluoro-N-{3-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-propyl}-2-(4-iodo- 2-methyl-phenylamino)-benzamide
	N,N-Diethyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide
10	N-Butyl-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide
	5-Chloro-N,N-diethyl-2-(4-iodo-2-methyl-phenylamino)-benzamide
	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N,N-dimethyl-benzamide
	5-Bromo-3,4-difluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl- phenylamino)-benzamide
15	N-(2,3-Dihydroxy-propyl)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)- benzamide
	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperidin-1- yl-ethyl)-benzamide
	3,4-Difluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)- benzamide
20	N-(2,3-Dihydroxy-propyl)-4-fluoro-2-(4-iodo-2-methyl-phenylamino)- benzamide
	3,4-Difluoro-N-(3-hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)- benzamide
25	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1- yl-ethyl)-benzamide
	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyridin-4-yl- ethyl)-benzamide
	4-Fluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide
30	5-Bromo-N-(3-dimethylamino-propyl)-3,4-difluoro-2-(4-iodo- 2-methylphenylamino)-benzamide



FORMULA (I) COMPOUND TABLE  
(page 3 of 9)

	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide
5	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide
	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide
10	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyridin-4-yl-ethyl)-benzamide
	N-(3-Dimethylamino-propyl)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide
	N-Benzyl-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide
15	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-hydroxy-ethyl)-benzamide
	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide
	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-1-yl-propyl)-benzamide
20	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-1-yl-propyl)-benzamide
	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-thiophen-2-yl-ethyl)-benzamide
25	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide
	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-morpholin-4-yl-ethyl)-benzamide
	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-pyridin-4-ylmethyl-benzamide
30	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-pyridin-4-ylmethyl-benzamide

FORMULA (I) COMPOUND TABLE  
(page 4 of 9)

	2-(4-Bromo-2-methyl-phenylamino)-N-(3-dimethylamino- propyl) -3,4-difluoro-benzamide
5	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-pyridin-4-ylmethyl-enzamide 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyridin-4-yl-ethyl)- benzamide
	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-pyridin-4-yl-ethyl)- benzamide
10	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(3-hydroxy-propyl)- benzamide
	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-pyrrolidin-1-yl-ethyl)- benzamide
	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-phenethyl-benzamide
15	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-thiophen-2-yl-ethyl)- benzamide
	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-pyridin-4-ylmethyl- benzamide
	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-phenethyl-benzamide
20	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-piperidin-1-yl-ethyl)- benzamide
	5-Chloro-N-{3-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-propyl}-2-(4-iodo-2-methyl- phenylamino)- benzamide
	5-Fluoro-N-{3-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-propyl}-2-(4-iodo-2-methyl- phenylamino)- benzamide
25	2-(4-Iodo-2-methyl-phenylamino)-5-nitro-N-pyridin-4-yl methyl-benzamide
	5-Bromo-N-{3-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-propyl}-2-(4-iodo-2-methyl- phenylamino)- benzamide
	5-Chloro-N-(2-diethylamino-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide
30	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperidin-1-yl-ethyl)- benzamide

FORMULA (I) COMPOUND TABLE  
(page 5 of 9)

	(3-Hydroxy-pyrrolidin-1-yl)-[5-nitro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-methanone
5	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide
	5-Bromo-N-(2-diethylamino-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide
	N-{2-[Bis-(2-hydroxy-ethyl)-amino]-ethyl}-5-chloro-2-(4-iodo-2-methyl-phenylamino)- benzamide
10	N-{2-[Bis-(2-hydroxy-ethyl)-amino]-ethyl}-5-bromo-2-(4-iodo-2-methyl-phenylamino)- benzamide
	N-{3-[4-(2-Hydroxy-ethyl)-piperazin-1-yl]-propyl}-2-(4-iodo-2-methyl-phenylamino)- benzamide
	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-pyridin-4-ylmethyl- benzamide
15	5-Bromo-2-(4-iodo-2-ethyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide
	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperidin-1-yl-ethyl)-benzamide
	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide
	5-Chloro-N-(3-dimethylamino-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide
20	N-{2-[Bis-(2-hydroxy-ethyl)-amino]-ethyl}-5-fluoro-2-(4-iodo-2-methyl-phenylamino)- benzamide
	5-Chloro-N-(3-hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide
	5-Chloro-N-(3-diethylamino-2-hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)- benzamide
25	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperidin-1-yl-ethyl)-benzamide
	5-Bromo-N-(3-hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide
	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-1-yl-propyl)-benzamide
	N-{2-[Bis-(2-hydroxy-ethyl)-amino]-ethyl}-2-(4-iodo-2-methyl-phenylamino)-5-nitro- benzamide
30	

FORMULA (I) COMPOUND TABLE  
(page 6 of 9)

	5-Chloro-N-(3-diethylamino-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide
5	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide
	5-Chloro-N-(2-diisopropylamino-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide
10	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-1-yl-propyl)-benzamide
	2-(4-Iodo-2-methyl-phenylamino)-5-nitro-N-(2-piperidin-1-yl-ethyl)-benzamide
	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperazin-1-yl-ethyl)-benzamide
15	N-(2-Diethylamino-ethyl)-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide
	5-Bromo-N-(3-dimethylamino-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide
	N-(3-Hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide
20	5-Fluoro-N-(3-hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)- benzamide
	N-(3-Diethylamino-propyl)-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide
	N-(3-Diethylamino-propyl)-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide
25	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide
	2-(4-Iodo-2-methyl-phenylamino)-5-nitro-N-(3-piperidin-1-yl-propyl)-benzamide
30	[5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-(2 or 3-hydroxy-pyrrolidin-1-yl)-methanone
	5-Bromo-N-(2-diisopropylamino-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide

FORMULA (I) COMPOUND TABLE  
(page 7 of 9)

	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide
5	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-1-yl-propyl)-benzamide
	[5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-4-(2-hydroxy-ethyl)-piperazin-1-yl)-methanone
10	N-(3-Diethylamino-2-hydroxy-propyl)-5-fluoro-2-(4-iodo-2-methyl-phenylamino)- benzamide
	N-Cyclopropyl-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide
	5-Chloro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide
	5-Fluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide
	N-Benzyloxy-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide
15	N-Benzyloxy-5-bromo-2-(4-iodo-2-methyl-phenylamino)-benzamide
	2-(4-Iodo-2-methyl-phenylamino)-5-nitro-N-(4-sulfamoyl-benzyl)- benzamide
	5-Bromo-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide
	N-(2-Hydroxy-ethyl)-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide
	N-(2-Hydroxy-ethyl)-2-(4-iodo-2-ethyl-phenylamino)-5-nitro-benzamide
20	2-(4-Iodo-2-methyl-phenylamino)-N-methyl-5-nitro-N-phenyl-benzamide
	5-Chloro-N-cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-benzamide
	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide
	N-Allyl-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide
	N-Benzyloxy-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide
25	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl-benzyl)-benzamide
	N-Allyl-5-chloro-2-(4-iodo-2-methyl-phenylamino)-benzamide
	N-Cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide
	5-Bromo-N-cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-benzamide
30	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide
	5-Iodo-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl-benzyl)- benzamide


FORMULA (I) COMPOUND TABLE  
(page 8 of 9)

	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl-benzyl)- benzamide
5	N-Allyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide 2-(4-Iodo-2-methyl-phenylamino)-5-nitro-N-(4-sulfamoyl-benzyl)- benzamide N-Allyl-5-bromo-2-(4-iodo-2-methyl-phenylamino)-benzamide 5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-benzamide
10	N-Cyclopropyl-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide 5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide N-Benzyloxy-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide N-Cyclohexyl-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide N-Allyl-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide
15	5-Iodo-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-benzamide 2-(4-Iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-5-nitro-benzamide 5-Iodo-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide N-Cyclohexyl-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide 5-Chloro-N-cyclohexyl-2-(4-iodo-2-methyl-phenylamino)-benzamide
20	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-benzamide 5-Bromo-N-cyclohexyl-2-(4-iodo-2-methyl-phenylamino)-benzamide 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)- benzamide N-Cyclohexyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide N-Benzyloxy-5-bromo-2-(4-iodo-2-methyl-phenylamino)-benzamide
25	N-Benzyloxy-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide 5-Chloro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide 5-Bromo-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide 2-(4-Iodo-2-methyl-phenylamino)-N-methyl-5-nitro-N-phenyl-benzamide 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide
30	

FORMULA (I) COMPOUND TABLE  
(page 9 of 9)

	N-(2-Hydroxy-ethyl)-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide
	5-Chloro-N-cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-benzamide
5	N-Allyl-5-chloro-2-(4-iodo-2-methyl-phenylamino)-benzamide
	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide
	N-(2-Hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide
	5-Fluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide
	5-Bromo-N-cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-benzamide
10	N-Cyclopropyl-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide
	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl-benzyl)- benzamide
	N-Cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide
	N-Allyl-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide
15	N-Benzyloxy-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide
	N-Allyl-5-bromo-2-(4-iodo-2-methyl-phenylamino)-benzamide
	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl-benzyl)- benzamide
	N-Allyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide
20	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-benzyl alcohol
	[5-Chloro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-methanol
	[2-(4-Iodo-2-methyl-phenylamino)-5-nitro-phenyl]-methanol
	[5-Bromo-2-(4-iodo-2-methyl-phenylamino)-phenyl]-methanol
	N-Allyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide.
25	

In another preferred embodiment, the MEK inhibitor is a compound of Formula II



5            In Formula (II),  $R_{1a}$  is hydrogen, hydroxy,  $C_1$ - $C_8$  alkyl,  $C_1$ - $C_8$  alkoxy, halo, trifluoromethyl, or CN.  $R_{2a}$  is hydrogen. Each of  $R_{3a}$ ,  $R_{4a}$ , and  $R_{5a}$  is independently selected from hydrogen, hydroxy, halo, trifluoromethyl,  $C_1$ - $C_8$  alkyl,  $C_1$ - $C_8$  alkoxy, nitro, CN, and  $(O \text{ or } NH)_m-(CH_2)_n-R_{9a}$ .  $R_{9a}$  is hydrogen, hydroxy,  $CO_2H$  or  $NR_{10a}R_{11a}$ ;  $n$  is 0-4; and  $m$  is 0 or 1. Each of

10             $R_{10a}$  and  $R_{11a}$  is independently hydrogen or  $C_1$ - $C_8$  alkyl, or taken together with the nitrogen to which they are attached can complete a 3- to 10-member cyclic ring optionally containing one, two, or three additional heteroatoms selected from O, S, NH, or N- $(C_1$ - $C_8$  alkyl).  $R_{6a}$  is hydrogen,  $C_1$ - $C_8$  alkyl,  $(CO)-(C_1$ - $C_8$  alkyl), aryl, aralkyl, or  $C_3$ - $C_{10}$  cycloalkyl.  $R_{7a}$  is hydrogen,  $C_1$ - $C_8$  alkyl,  $C_2$ - $C_8$  alkenyl,

15             $C_2$ - $C_8$  alkynyl,  $C_3$ - $C_{10}$  (cycloalkyl or cycloalkyl optionally containing a heteroatom selected from O, S, or  $NR_{9a}$ ). In Formula (II), any of the foregoing any of the foregoing alkyl, alkenyl, aryl, heteroaryl, heterocyclic, and alkynyl groups can be unsubstituted or substituted by halo, hydroxy,  $C_1$ - $C_6$  alkoxy, amino, nitro,  $C_1$ - $C_4$  alkylamino,  $di(C_1$ - $C_4)$ alkylamino,  $C_3$ - $C_6$  cycloalkyl, phenyl, phenoxy,  $C_3$ - $C_5$

20            heteroaryl or heterocyclic radical, or  $C_3$ - $C_5$  heteroaryloxy or heterocyclic radical-oxy; or  $R_{6a}$  and  $R_{7a}$  taken together with the N to which they are attached can complete a 5- to 10-membered cyclic ring, optionally containing one, two, or three additional heteroatoms selected from O, S, or  $NR_{10a}R_{11a}$ . The invention also



encompasses pharmaceutically acceptable salts, esters, amides or prodrugs of each of the disclosed compounds.

Preferred embodiments of Formula (II) are those structures wherein:

- 5 (a) R<sub>1a</sub> is H, methyl, fluoro, or chloro; (b) R<sub>2a</sub> is H; R<sub>3a</sub>, R<sub>4a</sub>, and R<sub>5a</sub> are each H, Cl, nitro, or F; (c) R<sub>6a</sub> is H; (d) R<sub>7a</sub> is methyl, ethyl, 2-propenyl, propyl, butyl, pentyl, hexyl, cyclopropylmethyl, cyclobutyl methyl, cyclopropylmethyl, or cyclopropylethyl; (e) the 4' position is I, rather than Br; (f) R<sub>4a</sub> is F at the 4 position, para to the CO-N-R<sub>6a</sub>-OR<sub>7a</sub> group and meta to the bridging nitrogen; (f) R<sub>3a</sub> or R<sub>5a</sub> is F; (g) at least one of R<sub>3a</sub>, R<sub>4a</sub>, and R<sub>5a</sub> is F; (h) R<sub>1a</sub> is methyl or  
10 chloro; or (i) or a combination of the above.

In a more preferred embodiment the MEK inhibitor is a compound selected from Formula (II) Compound Table below.

# FORMULA (II) COMPOUND TABLE

(page 1 of 5)

	5-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide
5	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(methoxy)-benzamide
	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(prop-2-ynyloxy)-benzamide
	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-phenoxyethoxy)-benzamide
	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-thienylmethoxy)-benzamide
	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(prop-2-enyloxy)-benzamide
10	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(cyclopropylmethoxy)-benzamide
	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(cyclopentoxo)-benzamide
	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-furylmethoxy)-benzamide
	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-ethoxy-benzamide
	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(but-2-enyloxy)-benzamide
15	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(cyclopropylmethoxy)-benzamide
	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(1-methylprop-2-ynyloxy)-benzamide
	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-phenylprop-2-ynyloxy)-benzamide
20	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-5-phenylpent-2-en-4-ynyloxy)-benzamide
	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(prop-2-ynyloxy)-benzamide
	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(propoxy)-benzamide
25	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(cyclobutyloxy)-benzamide
	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-thienylmethoxy)-benzamide
	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-methyl-prop-2-enyloxy)-benzamide
	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-phenoxyethoxy)-benzamide
30	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(but-2-enyloxy)-benzamide
	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(but-3-ynyloxy)-benzamide

FORMULA (II) COMPOUND TABLE  
(page 2 of 5)

	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-benzyl)-N-[5-(3-methoxy-phenyl)-3-methyl-pent-2-en-4-ynyloxy]-benzamide
5	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(prop-2-ynyloxy)-benzamide
	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-[3-(3-methoxy-phenyl)-prop-2-ynyloxy]-benzamide
10	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(thiopen-2-ylmethoxy)-benzamide
	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(pyridin-3-ylmethoxy)-benzamide
	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-(2-fluorophenyl)-prop-2-ynyloxy)-benzamide
15	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(ethoxy)-benzamide
	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(cyclopropylmethoxy)-benzamide
	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(isopropoxy)-benzamide
20	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-but-3-ynyloxy)-benzamide
	5-Chloro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide
	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(tetrahydro-pyran-2-yloxy)-benzamide
25	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-methoxy-benzamide
	4-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-phenylmethoxy-benzamide
	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-phenylmethoxy-benzamide
	5-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide
	5-Iodo-2-(4-iodo-2-methyl-phenylamino)-N-phenylmethoxy-benzamide
30	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(tetrahydropyran-2-yloxy)-benzamide

FORMULA (II) COMPOUND TABLE  
(page 3 of 5)

	3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(3-phenylprop-2-ynyloxy)-benzamide
5	3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(3-furylmethoxy)-benzamide
	3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(2-thienylmethoxy)-benzamide
	3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(but-3-ynyloxy)-benzamide
10	3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(2-methyl-prop-2-ynyloxy)-benzamide
	3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(but-2-ynyloxy)-benzamide
	3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(methoxy)-benzamide
	3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(ethoxy)-benzamide
	3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(cyclobutoxy)-benzamide
15	3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(isopropoxy)-benzamide
	3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(2-phenoxymethoxy)-benzamide
	3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(cyclopropylmethoxy)-benzamide
20	3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(n-propoxy)-benzamide
	3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(1-methyl-prop-2-ynyloxy)-benzamide
	3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(3-(3-fluorophenyl)-prop-2-ynyloxy)-benzamide
25	3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(4,4-dimethylpent-2-ynyloxy)-benzamide
	3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(cyclopentoxymethyl)-benzamide
	3,4,5-Trifluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide
	5-Chloro-3,4-difluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide
30	5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-hydroxy-benzamide
	N-Hydroxy-2-(4-iodo-2-methyl-phenylamino)-4-nitro-benzamide
	3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-hydroxy-benzamide

FORMULA (II) COMPOUND TABLE  
(page 4 of 5)

	5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-hydroxy-benzamide
	5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-benzamide
5	2-(2-Fluoro-4-iodo-phenylamino)-N-hydroxy-4-nitro-benzamide
	2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-hydroxy-benzamide
	5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-benzamide
	5-Bromo-2-(2-bromo-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-benzamide
	2-(2-Chloro-4-iodo-phenylamino)-N-hydroxy-4-methyl-benzamide
10	2-(2-Bromo-4-iodo-phenylamino)-3,4,5-trifluoro-N-hydroxy-benzamide
	2-(2-Bromo-4-iodo-phenylamino)-5-chloro-3,4-difluoro-N-hydroxy-benzamide
	2-(2-Bromo-4-iodo-phenylamino)-N-hydroxy-4-nitro-benzamide
	4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-hydroxy-benzamide
	3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-hydroxy-benzamide
15	2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-hydroxy-benzamide
	2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-benzamide
	2-(2-Bromo-4-iodo-phenylamino)-4-fluoro-N-hydroxy-benzamide
	2-(2-Bromo-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-benzamide
	N-Cyclopropylmethoxy-3,4,5-trifluoro-2-(4-iodo-2-methyl-phenylamino)-
20	benzamide
	5-Chloro-N-cyclopropylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-
	benzamide
	5-Bromo-N-cyclopropylmethoxy-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-
	benzamide
25	N-Cyclopropylmethoxy-2-(4-iodo-2-methyl-phenylamino)-4-nitro-benzamide
	N-Cyclopropylmethoxy-3,4,5-trifluoro-2-(2-fluoro-4-iodo-phenylamino)-
	benzamide
	5-Chloro-N-cyclopropylmethoxy-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-
	benzamide
30	5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-
	benzamide
	N-Cyclopropylmethoxy-2-(2-fluoro-4-iodo-phenylamino)-4-nitro-benzamide

FORMULA (II) COMPOUND TABLE  
(page 5 of 5)

	2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4,5-trifluoro- benzamide
5	5-Chloro-2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro- benzamide
	5-Bromo-2-(2-bromo-4-iodo-phenylamino)-N-ethoxy-3,4-difluoro-benzamide
	2-(2-Chloro-4-iodo-phenylamino)-N-ethoxy-4-nitro-benzamide
10	2-(2-Bromo-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4,5-trifluoro- benzamide
	2-(2-Bromo-4-iodo-phenylamino)-5-chloro-N-cyclopropylmethoxy-3,4-difluoro- benzamide
	2-(2-Bromo-4-iodo-phenylamino)-N-cyclopropylmethoxy-4-nitro-benzamide
	N-Cyclopropylmethoxy-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide
15	N-Cyclopropylmethoxy-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide
	2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-4-fluoro-benzamide
	2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide
	2-(2-Bromo-4-iodo-phenylamino)-N-cyclopropylmethoxy-4-fluoro-benzamide
20	2-(2-Bromo-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro- benzamide.

In a further preferred embodiment of this invention, a mitotic inhibitor is administered to a patient suffering from cancer and in need of treatment in combination with a selective MEK inhibitor selected from:

2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-  
3,4-difluorobenzamide;

2-(2-Methyl-4-iodophenylamino)-N-hydroxy-4-fluorobenzamide;

2-(2-Methyl-4-iodophenylamino)-N-hydroxy-3,4-difluoro-  
5-bromobenzamide;

2-(2-Methyl-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluoro-  
5-bromobenzamide;

2-(2-Methyl-4-iodophenylamino)-N-cyclobutylmethoxy-3,4-difluoro-  
5-bromobenzamide;

2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluoro-  
5-bromobenzamide;

2-(2-Chloro-4-iodophenylamino)-N-hydroxy-3,4-difluoro-  
5-bromobenzamide;

2-(2-Chloro-4-iodophenylamino)-N-cyclobutylmethoxy-  
3,4-difluorobenzamide;

2-(2-Chloro-4-iodophenylamino)-N-hydroxy-4-fluorobenzamide;

2-(2-Methyl-4-iodophenylamino)-N-hydroxy-3,4-difluorobenzamide;  
2-(2-Methyl-4-iodophenylamino)-N-cyclopropylmethoxy-  
3,4,5-trifluorobenzamide;and

2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-  
4-fluorobenzamide; and the benzoic acid derivatives thereof. For example, the  
benzoic acid derivative of 2-(2-Methyl-4-iodophenylamino)-N-  
cyclopropylmethoxy-3,4,5-trifluorobenzamide is 2-(2-Methyl-  
4-iodophenylamino)-3,4,5-trifluorobenzoic acid.

Additional preferred compounds include

2-(2-chloro-4-iodophenylamino)-5-chloro-N-cyclopropylmethoxy -3,4-  
difluorobenzamide;

2-(4-iodophenylamino)-N-cyclopropylmethoxy-5-chloro-3,4-  
difluorobenzamide;

2-(4-iodophenylamino)-5-chloro-3,4-difluorobenzoic acid;  
2-(2-chloro-4-iodophenylamino)-5-chloro-3,4-difluorobenzoic acid;  
5-chloro-3,4-difluoro-2-(4-iodo-2-methylphenylamino)-benzoic acid; and  
5-chloro-N-cyclopropylmethoxy-3,4-difluoro-2-(4-iodo-2-  
5 methylphenylamino)-benzamide.

The most preferred embodiment of this invention is a combination of  
paclitaxel and the MEK inhibitor 2-(2-chloro-4-iodophenylamino)-N-  
cyclopropylmethoxy-3,4-difluorobenzamide.

10 The invention further provides methods of synthesis and synthetic  
intermediates.

Other features and advantages of the invention are apparent from the  
figures, description, examples, and claims below.

#### BRIEF DESCRIPTION OF THE FIGURES

15 FIG. 1 shows the effect on apoptosis in colon 26 carcinoma cells of  
paclitaxel (Taxol®, paclitaxel injection, Bristol-Meyers Squibb) alone, of  
2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide  
alone, and of the combination of the two agents.

FIG. 2 shows a second experiment measuring the effect on apoptosis in  
colon 26 carcinoma cells of Taxol alone and of 2-(2-chloro-4-iodophenylamino)-  
20 N-cyclopropylmethoxy-3,4-difluorobenzamide alone, and the combination of the  
two agents.

FIG. 3 shows the effect on apoptosis in HT-29 colon carcinoma cells  
treated with Taxol alone, with 2-(2-chloro-4-iodophenylamino)-N-  
cyclopropylmethoxy-3,4-difluorobenzamide alone, and the combination of the  
25 two agents.



## DETAILED DESCRIPTION OF THE INVENTION

This invention provides a method of treating cancer in a patient which comprises administering to a patient suffering from cancer and in need of treatment an antitumor effective amount of a mitotic inhibitor in combination with an antitumor effective amount of a selective MEK inhibitor. Preferred mitotic inhibitors to be used according to this invention include paclitaxel, docletaxel, vincristine, vinblastine, vinorelbine, and the fluorinated derivative of vinorelbine, vinflunine. The invention is preferably practiced by administering a phenyl amine MEK inhibitor of Formula I or Formula II in combination with a mitotic inhibitor, especially paclitaxel. Such MEK phenyl amine compounds are specific MEK 1 and MEK 2 inhibitors, meaning that they inhibit these enzymes without inhibiting other enzymes to a great extent.

The mammals to be treated according to this invention are patients, both humans and animals such as horses and dogs, who have developed a cancer and who are in need of treatment. Those skilled in the medical art are readily able to identify individual patients who are afflicted with cancer and who are in need of treatment. Typical cancers to be treated according to this invention are colon cancer, pancreatic cancer, breast cancer, ovarian cancer, lung cancer and other cancers susceptible to treatment with mitotic inhibitors such as paclitaxel and/or MEK inhibitors.

As noted above, the MEK inhibitors can be formulated for administration by the oral or parenteral routes. They can also be administered transdermally, as skin patches or lotions, or as suppositories. While the MEK inhibitors can be formulated with paclitaxel, for instance in solution for intravenous injection or infusion, the active agents will more typically be formulated individually in their normal preparations, and will be administered individually, but generally at about the same time, or together in a course of treatment. For example, paclitaxel is available commercially in sterile nonpyrogenic solutions containing polyoxyethylated castor oil and dehydrated alcohol. The product is available in packages of 30 mg/5 mL and 100 mg/16.7 mL. The MEK inhibitor and paclitaxel can be formulated individually and packaged together, in a kit for example, for

convenience in usage. Alternatively, the agents can be formulated together in a single formulation, in which case the paclitaxel will be present at concentrations ranging from about 1 to about 1000 parts by weight relative to the MEK inhibitor, and the MEK inhibitor will be present at concentrations of about 1000 to about 1 part by weight relative to the paclitaxel. Generally, the agents will be administered at about equal doses, or as otherwise approved by health regulatory agencies.

Further examples of combinations provided by this invention include:

(a) vincristine administered in combination with 2-(2-methyl-4-iodophenylamino)-N-hydroxy-3,4-difluoro-5-bromobenzamide; (b) the mitotic inhibitor docetaxel (Taxotere® Rhone Poulenc Rorer) administered in combination with the selective MEK inhibitor 2-(2-chloro-4-iodophenylamino)-N-hydroxy-3,4-difluoro-5-bromobenzamide; (c) an especially preferred method, the mitotic inhibitor vinorelbine tartrate (Navelbine® Glaxo-Wellcome) administered in combination with the selective MEK inhibitor 2-(2-amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran; (d) the mitotic inhibitor vinflunine, the fluoro derivative of vinorelbine, administered in combination with the selective MEK inhibitor is 2-(2-methyl-4-iodophenylamino)-N-hydroxy-4-fluorobenzamide.

Some of the compounds of the combinations of the present are MEK inhibitors, which also can be used individually to treat septic shock. A MEK inhibitor is a compound that shows MEK inhibition when tested in the assays titled "Enzyme Assays" in United States Patent Number 5,525,625, column 6, beginning at line 35. The complete disclosure of United States Patent Number 5,525,625 is hereby incorporated by reference. An example of a MEK inhibitor is 2-(2-amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran. Specifically, a compound is a MEK inhibitor if a compound shows activity in the assay titled "Cascade Assay for Inhibitors of the MAP Kinase Pathway," column 6, line 36 to column 7, line 4 of the United States Patent Number 5,525,625 and/or shows activity in the assay titled "In Vitro MEK Assay" at column 7, lines 4 to 27 of the above-referenced patent.

Other features and advantages of the invention are apparent from the description, examples, and claims below.

#### A. Terms

5 Some of the terms used herein are defined below and by their usage throughout this disclosure.

The term “patient” means all animals including humans. Examples of patients include humans, cows, dogs, cats, goats, sheep, horses, and pigs.

10 As used herein, the term “aryl” means a cyclic, bicyclic, or tricyclic aromatic ring moiety having from five to twelve carbon atoms. Examples of typical aryl groups include phenyl, naphthyl, and fluorenyl. The aryl may be substituted by one, two, or three groups selected from fluoro, chloro, bromo, iodo, alkyl, hydroxy, alkoxy, nitro, amino, alkylamino, or dialkylamino. Typical substituted aryl groups include 3-fluorophenyl, 3,5-dimethoxyphenyl, 4-nitronaphthyl, 2-methyl-4-chloro-7-aminofluorenyl, and the like.

15 The term “aryloxy” means an aryl group bonded through an oxygen atom, for example phenoxy, 3-bromophenoxy, naphthyloxy, and 4-methyl-1-fluorenyloxy.

20 “Heteroaryl” means a cyclic, bicyclic, or tricyclic aromatic ring moiety having from four to eleven carbon atoms and one, two, or three heteroatoms selected from O, S, or N. Examples include furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl, oxazolyl, xanthenyl, pyronyl, indolyl, pyrimidyl, naphthyridyl, pyridyl, benzinnidazolyl, and triazinyl. The heteroaryl groups can be unsubstituted or substituted by one, two, or three groups selected from fluoro, chloro, bromo, iodo, alkyl, hydroxy, alkoxy, nitro, amino, alkylamino, or

25 dialkylamino. Examples of substituted heteroaryl groups include chloropyranyl, methylthienyl, fluoropyridyl, amino-1,4-benzisoxazinyl, nitroisoquinoliny, and hydroxyindolyl.

30 The heteroaryl groups can be bonded through oxygen to make heteroaryloxy groups, for example thienyloxy, isothiazolyloxy, benzofuranyloxy, pyridyloxy, and 4-methylisoquinolinyloxy.

The term “alkyl” means straight and branched chain aliphatic groups. Typical alkyl groups include methyl, ethyl, isopropyl, tert.-butyl, 2,3-dimethylhexyl, and 1,1-dimethylpentyl. The alkyl groups can be unsubstituted or substituted by halo, hydroxy, alkoxy, amino, alkylamino, dialkylamino, cycloalkyl, aryl, aryloxy, heteroaryl, or heteroaryloxy, as those terms are defined herein. Typical substituted alkyl groups include chloromethyl, 3-hydroxypropyl, 2-dimethylaminobutyl, and 2-(hydroxymethylamino)ethyl. Examples of aryl and aryloxy substituted alkyl groups include phenylmethyl, 2-phenylethyl, 3-chlorophenylmethyl, 1,1-dimethyl-3-(2-nitrophenoxy)butyl, and 3,4,5-trifluoronaphthylmethyl. Examples of alkyl groups substituted by a heteroaryl or heteroaryloxy group include thienylmethyl, 2-furylethyl, 6-furyloxyoctyl, 4-methylquinolyloxymethyl, and 6-isothiazolylhexyl. Cycloalkyl substituted alkyl groups include cyclopropylmethyl, 2-cyclohexylethyl, piperidyl-2-methyl, 2-(piperidin-1-yl)-ethyl, 3-(morpholin-4-yl)propyl.

“Alkenyl” means a straight or branched carbon chain having one or more double bonds. Examples include but-2-enyl, 2-methyl-prop-2-enyl, 1,1-dimethyl-hex-4-enyl, 3-ethyl-4-methyl-pent-2-enyl, and 3-isopropyl-pent-4-enyl. The alkenyl groups can be substituted with halo, hydroxy, alkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy, heteroaryl, or heteroaryloxy, for example 2-bromoethenyl, 3-hydroxy-2-butenyl, 1-aminoethenyl, 3-phenylprop-2-enyl, 6-thienyl-hex-2-enyl, 2-furyloxy-but-2-enyl, and 4-naphthyloxy-hex-2-enyl.

“Alkynyl” means a straight or branched carbon chain having at least one triple bond. Typical alkynyl groups include prop-2-ynyl, 2-methyl-hex-5-ynyl, 3,4-dimethyl-hex-5-ynyl, and 2-ethyl-but-3-ynyl. The alkynyl groups can be substituted as the alkyl and alkenyl groups, for example, by aryl, aryloxy, heteroaryl, or heteroaryloxy, for example 4-(2-fluorophenyl)-but-3-ynyl, 3-methyl-5-thienylpent-4-ynyl, 3-phenoxy-hex-4-ynyl, and 2-furyloxy-3-methyl-hex-4-ynyl.

The alkenyl and alkynyl groups can have one or more double bonds or triple bonds, respectively, or a combination of double and triple bonds. For example, typical groups having both double and triple bonds include hex-2-en-4-ynyl, 3-methyl-5-phenylpent-2-en-4-ynyl, and 3-thienyloxy-hex-3-en-5-ynyl.

The term "cycloalkyl" means a nonaromatic ring or fused rings. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, bicycloheptyl, adamantyl, and cyclohexyl. The ring can optionally contain one, two, or three heteroatoms selected from O, S, or N. Such groups include tetrahydrofuryl, tetrahydropyrrolyl, octahydrobenzofuranyl, morpholinyl, piperazinyl, pyrrolidinyl, piperidinyl, octahydroindolyl, and octahydrobenzothiofuranyl. The cycloalkyl groups can be substituted with the same substituents as an alkyl and alkenyl groups, for example, halo, hydroxy, aryl, and heteroaryloxy. Examples include 3-hydroxycyclohexyl, 2-aminocyclopropyl, 2-phenylpyrrolidinyl, and 3-thienylmorpholine-1-yl.

## B. Administration and Formulation

The MEK inhibitors of the present method can be administered to a patient as part of a pharmaceutically acceptable composition. The compositions can be administered to humans and animals either orally, rectally, parenterally (intravenously, intramuscularly, or subcutaneously), intracisternally, intravaginally, intraperitoneally, intravesically, locally (powders, ointments, or drops), or as a buccal or nasal spray.

Compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents, or vehicles include water, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.

These compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be

desirable to include isotonic agents, for example sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.

5               Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders, as for example,  
10               carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, (c) humectants, as for example, glycerol, (d) disintegrating agents, as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate, (e) solution retarders, as for example paraffin, (f) absorption accelerators, as for example, quaternary  
15               ammonium compounds, (g) wetting agents, as for example, cetyl alcohol and glycerol monostearate, (h) adsorbents, as for example, kaolin and bentonite, and (i) lubricants, as for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents.

20               Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethyleneglycols, and the like.

              Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and others well-  
25               known in the art. They may contain opacifying agents, and can also be of such composition that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Examples of embedding compositions which can be used are polymeric substances and waxes. The active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the  
30               above-mentioned excipients.

              Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. In addition to the

active compounds, the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide, oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols, and fatty acid esters of sorbitan or mixtures of these substances, and the like.

Besides such inert diluents, the composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

Suspensions, in addition to the active compounds, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.

Compositions for rectal administrations are preferably suppositories which can be prepared by mixing the compounds of the present invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethyleneglycol, or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore, melt in the rectum or vaginal cavity and release the active component.

Dosage forms for topical administration of a compound of this invention include ointments, powders, sprays, and inhalants. The active component is admixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants as may be required. Ophthalmic formulations, eye ointments, powders, and solutions are also contemplated as being within the scope of this invention.

The compounds of the present method can be administered to a patient at dosage levels in the range of about 0.1 to about 1000 mg per day. For a normal human adult having a body weight of about 70 kg, a dosage in the range of about 0.01 to about 100 mg per kg of body weight per day is preferable. The specific dosage used, however, can vary. For example, the dosage can depend on a

numbers of factors including the requirements of the patient, the severity of the condition being treated, and the pharmacological activity of the compound being used. The determination of optimum dosages for a particular patient is well-known to those skilled in the art.

5           The compounds of the present method can be administered as pharmaceutically acceptable salts, esters, amides, or prodrugs. The term “pharmaceutically acceptable salts, esters, amides, and prodrugs” as used herein refers to those carboxylate salts, amino acid addition salts, esters, amides, and prodrugs of the compounds of the present invention which are, within the scope of  
10           sound medical judgment, suitable for contact with the tissues of patients without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention.

          The term “salts” refers to the relatively non-toxic, inorganic and organic  
15           acid addition salts of compounds of the present invention. These salts can be prepared *in situ* during the final isolation and purification of the compounds or by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate,  
20           oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactiobionate and laurylsulphonate salts, and the like. These may include cations based on the alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium and the like, as well as nontoxic  
25           ammonium, quaternary ammonium, and amine cations including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. (See, for example, S.M. Berge, et al., “Pharmaceutical Salts,” *J. Pharm. Sci.*, 1977;66:1-19 which is incorporated herein by reference.)

30           Examples of pharmaceutically acceptable, non-toxic esters of the compounds of this invention include C<sub>1</sub>-C<sub>6</sub> alkyl esters wherein the alkyl group is



a straight or branched chain. Acceptable esters also include C<sub>5</sub>-C<sub>7</sub> cycloalkyl esters as well as arylalkyl esters such as, but not limited to benzyl. C<sub>1</sub>-C<sub>4</sub> alkyl esters are preferred. Esters of the compounds of the present invention may be prepared according to conventional methods.

5           Examples of pharmaceutically acceptable, non-toxic amides of the compounds of this invention include amides derived from ammonia, primary C<sub>1</sub>-C<sub>6</sub> alkyl amines and secondary C<sub>1</sub>-C<sub>6</sub> dialkyl amines wherein the alkyl groups are straight or branched chain. In the case of secondary amines the amine may also be in the form of a 5 or 6 membered heterocycle containing one nitrogen atom.  
10       Amides derived from ammonia, C<sub>1</sub>-C<sub>3</sub> alkyl primary amines and C<sub>1</sub>-C<sub>2</sub> dialkyl secondary amines are preferred. Amides of the compounds of the invention may be prepared according to conventional methods.

          The term "prodrug" refers to compounds that are rapidly transformed *in vivo* to yield the parent compound of the above formula, for example, by  
15       hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference.

20           In addition, the compounds of the present method can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the present invention.


          Some of the compounds of the present method can exist in different  
25       stereoisometric forms by virtue of the presence of chiral centers. It is contemplated that all stereoisometric forms of the compounds as well as mixtures thereof, including racemic mixtures, form part of this invention.

### C. Synthesis

The examples presented below are intended to illustrate particular embodiments of the invention and are not intended to limit the scope of the specification, including the claims, in any way. After the priority date of the present disclosure, related syntheses and MEK inhibition data were also published in WO 99/01421 and WO 99/01426, hereby incorporated by reference.

The 2-(4-bromo and 4-iodo phenylamino)-benzoic acid derivatives of Formula I can be prepared from commercially available starting materials utilizing synthetic methodologies well-known to those skilled in organic chemistry. A typical synthesis is carried out by reacting a 4-bromo or 4-iodo aniline with a benzoic acid having a leaving group at the 2-position to give a 2-(phenylamino)-benzoic acid. This process is depicted in Scheme 1.

Scheme 1



where L is a leaving group, for example halo such as fluoro.

The reaction of aniline and the benzoic acid derivative generally is accomplished by mixing the benzoic acid with an equimolar quantity or excess of

the aniline in an unreactive organic solvent such as tetrahydrofuran or toluene, in the presence of a base such as lithium diisopropylamide, n-butyl lithium, sodium hydride, triethylamine, and Hunig's base. The reaction generally is carried out at a temperature of about -78°C to about 100°C, and normally is complete within about 2 hours to about 4 days. The product can be isolated by removing the solvent, for example by evaporation under reduced pressure, and further purified, if desired, by standard methods such as chromatography, crystallization, or distillation.


The 2-(phenylamino)-benzoic acid (e.g., Formula I, where R<sub>7</sub> is hydrogen) can be reacted with an organic or inorganic base such as pyridine, triethylamine, calcium carbonate, or sodium hydroxide to produce a pharmaceutically acceptable salt. The free acids can also be reacted with an alcohol of the formula HOR<sub>7</sub> (where R<sub>7</sub> is other than hydrogen, for example methyl) to produce the corresponding ester. Reaction of the benzoic acid with an alcohol can be carried out in the presence of a coupling agent. Typical coupling reagents include 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ), 1,3-dicyclohexylcarbodiimide (DCC), bromo-tris(pyrrolidino)- phosphonium hexafluorophosphate (PyBrOP), and (benzotriazolyloxy) tripyrrolidino phosphonium hexafluorophosphate (PyBOP). The phenylamino benzoic acid and alcohol derivative normally are mixed in approximately equimolar quantities in an unreactive organic solvent such as dichloromethane, tetrahydrofuran, chloroform, or xylene, and an equimolar quantity of the coupling reagent is added. A base such as triethylamine or diisopropylethylamine can be added to act as an acid scavenger if desired. The coupling reaction generally is complete after about 10 minutes to 2 hours, and the product is readily isolated by removing the reaction solvent, for instance by evaporation under reduced pressure, and purifying the product by standard methods such as chromatography or crystallizations from solvents such as acetone, diethyl ether, or ethanol.

The benzamides of the invention, Formula I where Z is CONR<sub>6</sub>R<sub>7</sub>, are readily prepared by reacting the foregoing benzoic acids with an amine of the formula HNR<sub>6</sub>R<sub>7</sub>. The reaction is carried out by reacting approximately

equimolar quantities of the benzoic acid and amine in an unreactive organic solvent in the presence of a coupling reagent. Typical solvents are chloroform, dichloromethane, tetrahydrofuran, benzene, toluene, and xylene. Typical coupling reagents include DCC, EEDQ, PyBrOP, and PyBOP. The reaction is generally complete after about 10 minutes to about 2 hours when carried out at a temperature of about 0°C to about 60°C. The product amide is readily isolated by removing the reaction solvent, for instance by evaporation, and further purification can be accomplished by normal methods such as chromatography, crystallization, or distillation. The hydrazides ( $z = \text{CONHNR}_{10}\text{R}_{11}$ ) are similarly prepared by coupling a benzoic acid with a hydrazine of the formula  $\text{H}_2\text{HNR}_{10}\text{R}_{11}$ .

The benzyl alcohols of the invention, compounds of Formula I where Z is  $\text{CH}_2\text{OR}_6$  and  $\text{R}_6$  is hydrogen, are readily prepared by reduction of the corresponding benzoic acid according to the following Scheme 2.

Scheme 2



Typical reducing agents commonly employed include borane in tetrahydrofuran. The reduction normally is carried out in an unreactive organic solvent such as tetrahydrofuran, and generally is complete within about 2 hours to about 24 hours when conducted at a temperature of about 0°C to about 40°C.

The following detailed examples illustrate specific compounds provided by this invention.

## EXAMPLE 1

### 4-Fluoro-2-(4-iodo-2-methylphenylamino)benzoic acid

To a stirring solution comprised of 3.16 g (0.0133 mol) of 2-amino-5-iodotoluene in 5 mL of tetrahydrofuran at -78°C was added 10 mL (0.020 mol) of a 2.0 M lithium diisopropylamide in tetrahydrofuran/heptane/ethenylbenzene (Aldrich) solution. The resulting green suspension was stirred vigorously for 15 minutes, after which time a solution of 1.00 g (0.00632 mol) of 2,4-difluorobenzoic acid in 10 mL of tetrahydrofuran was added. The reaction temperature was allowed to increase slowly to room temperature, at which temperature it was stirred for 2 days. The reaction mixture was concentrated. Aqueous HCl (10%) was added to the concentrate, and the solution was extracted with dichloromethane. The organic phase was dried (MgSO<sub>4</sub>) and then boiled over a steambath to low volume and cooled to room temperature. The off-white fibers were collected by vacuum filtration, rinsed with hexanes, and vacuum-oven dried. (76°C; ca. 10 mm of Hg) to afford 1.10 g (47%) of the desired material; mp 224-229.5°C;

<sup>1</sup>H NMR (400 MHz; DMSO): δ 9.72 (s, 1H), 7.97 (dd, 1H, J = 7.0, 8.7 Hz), 7.70 (d, 1H, J = 1.5 Hz), 7.57 (dd, 1H, J = 8.4, 1.9 Hz), 7.17 (d, 1H, J = 8.2 Hz), 6.61-6.53 (m, 2H), 2.18 (s, 3H); <sup>13</sup>C NMR (100 MHz; DMSO): δ 169.87, 167.60, 165.12, 150.17, 150.05, 139.83, 138.49, 136.07, 135.31, 135.20, 135.07, 125.60, 109.32, 105.09, 104.87, 99.72, 99.46, 89.43, 17.52;

<sup>19</sup>F NMR (376 MHz; DMSO): δ -104.00 to -104.07 (m);

IR (KBr) 1670 (C = O stretch) cm<sup>-1</sup>;

MS (CI) M+1 = 372.

Analysis calculated for C<sub>14</sub>H<sub>11</sub>FINO<sub>2</sub>: C, 45.31; H, 2.99; N, 3.77.

Found: C, 45.21; H, 2.77; N, 3.64.

## EXAMPLES 2-30

By following the general procedure of Example 1, the following benzoic acids and salts of Formula (I) were prepared.

Example No.	Compound	MP °C
2	3,4,5-Trifluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid	206-210
3	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid	240.5-244.5
4	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid	259.5-262
5	5-Chloro-2-(2-chloro-4-iodo-phenylamino)-benzoic acid	255-260
6	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid	234-238
7	Sodium 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-benzoate	310-320 DEC
8	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-benzoic acid	239.5-240
9	2-(2-Chloro-4-iodo-phenylamino)-5-nitro-benzoic acid	289-293
10	4-Fluoro-2-(3-fluoro-4-iodo-2-methyl-phenylamino)-benzoic acid	233-235
11	2-(4-Iodo-2-methyl-phenylamino)-5-nitro-benzoic acid	264-267
12	2-(2-Fluoro-4-iodo-phenylamino)-5-nitro-benzoic acid	256-258
13	2-(4-Bromo-2-methyl-phenylamino)-4-fluoro-benzoic acid	218.5-220
14	2-(2-Bromo-4-iodo-phenylamino)-5-nitro-benzoic acid	285-288 DEC
15	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-benzoic acid	230-234
16	3-Fluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid	218-221
17	3,4-Difluoro-2-(4-iodo-2-methoxy-phenylamino)-benzoic acid	230-233
18	4-Chloro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid	245-255 DEC
19	2-(4-Iodo-2-methyl-phenylamino)-benzoic acid	218-223
20	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid	243-46
21	5-Iodo-2-(4-iodo-2-methyl-phenylamino)-benzoic acid	241-245

Example No.	Compound	MP °C
22	2,3,5-Trifluoro-4-(4-iodo-2-methyl-phenylamino)-benzoic acid	218-222
23	4-Fluoro-2-(3-chloro-4-iodo-2-methyl-phenylamino)-benzoic acid	248-252.5
24	2-(4-Iodo-phenylamino)-5-methoxy-benzoic acid	208-211
25	3-Chloro-2-(2-chloro-4-iodo-phenylamino)-benzoic acid	232-233
26	2-Fluoro-6-(4-iodo-2-methyl-phenylamino)-benzoic acid	179-182
27	4-Fluoro-2-(2,3-dimethyl-4-iodo-2-methyl-phenylamino)benzoic acid	258-261
28	5-Methyl-2-(4-iodo-2-methyl-phenylamino)-benzoic acid	209.5-211
29	2-Chloro-6-(4-iodo-2-methyl-phenylamino)-benzoic acid	171-175
30	2-(4-Iodo-2-methyl-phenylamino)-4-nitro-benzoic acid	251-263

### EXAMPLE 31

#### 5-Chloro-N-(2-hydroxyethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide

To a stirring solution comprised of 0.1020 g (0.2632 mmol) of 5-chloro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid, 0.1 mL (1.7 mmol) of ethanolamine, and 0.05 mL (0.29 mmol) of diisopropylethylamine in 5 mL of a 1:1 (v/v) tetrahydrofuran-dichloromethane solution was added 0.15 g (0.29 mmol) of solid PyBOP powder directly. The reaction mixture was stirred at room temperature overnight. The solvent was removed in vacuo. The crude residue was partitioned between ether (50 mL) and 10% aqueous hydrochloric acid (50 mL). The organic phase was washed with 10% aqueous sodium hydroxide (50 mL), dried (MgSO<sub>4</sub>) and concentrated in vacuo to afford a yellow-brown oil which was crystallized from hexanes-ether to afford 0.0831 g (73%) of a green-yellow powder; mp 120-121°C;

<sup>1</sup>H NMR (400 MHz; CDCl<sub>3</sub>): δ 9.11 (s, 1H), 7.56 (d, 1H, J = 1.4 Hz), 7.46-7.41 (m, 2H), 7.20 (dd, 1H, J = 8.9, 2.4 Hz), 7.00 (t, 2H, J = 9.6 Hz), 6.55 (broad t, 1H), 3.86 (t, 2H, J = 5.0 Hz), 3.61 (dd, 2H, J = 10.1, 5.5 Hz), 2.23 (s, 3H), 1.56 (broad s, 1H);

IR (KBr) 3297 (O-H stretch), 1627 (C = O stretch)  $\text{cm}^{-1}$ ;

MS (CI)  $M+1 = 431$ .

Analysis calculated for  $\text{C}_{16}\text{H}_{16}\text{ClIN}_2\text{O}_2$ :

C, 44.62; H, 3.74; N, 6.50.

5 Found: 44.63; H, 3.67; N, 6.30.

#### EXAMPLES 32-48

By following the general procedure of Example 31, the following benzamides were prepared by reacting the corresponding benzoic acid with the corresponding amine.

Example No.	Compound	MP °C
32	4-Methoxy-N-(4-methoxy-phenyl)-3-nitro-benzamide	153.5-156
33	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	158
34	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-benzamide	102.5-104.5
35	N-Ethyl-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	90-91
36	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N,N-dimethyl-benzamide	oil
37	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(1H-tetrazol-5-yl)-benzamide	285-288 DEC
38	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-benzamide	180-182
39	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N,N-dimethyl-benzamide	137-138



Example No.	Compound	MP °C
40	[5-Chloro-2-(4-iodo-2-methyl-phenylamino)-benzoylamino]-acetic acid	170-173
41	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-propyl-benzamide	69-71
42	5-Bromo-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	132-133.4
43	N,N-Diethyl-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	oil
44	4-Fluoro-N-{3-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-propyl}-2-(4-iodo-2-methyl-phenylamino)-benzamide	122-124
45	N,N-Diethyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide	91-93
46	N-Butyl-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	97-99
47	5-Chloro-N,N-diethyl-2-(4-iodo-2-methyl-phenylamino)-benzamide	118-120
48	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N,N-dimethyl-benzamide	142.5-144

#### EXAMPLE 49

##### 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-benzyl alcohol

4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid (0.50 g, 1.35 mmol) was dissolved in 6 mL (6 mmol) of cold 1.0 M borane-tetrahydrofuran complex in tetrahydrofuran solution. The reaction mixture was stirred under nitrogen atmosphere at room temperature overnight. The reaction was quenched with 80 mL of methanol. Concentration in vacuo produced a clear tan oil which was purified by MPLC. Elution with dichloromethane afforded 0.4285 g (89%) of a white solid; mp 99-100.5°C;

<sup>1</sup>H NMR (400 MHz; DMSO): δ 7.57 (d, 1H, J=1.7 Hz), 7.45 (dd, 1H, J=8.4, 1.9 Hz), 7.39 (s, 1H), 7.29 (t, 1H, J=7.5 Hz), 6.89 (d, 1H, J=8.4 Hz), 6.67-6.60 (m, 1H), 5.47 (t, 1H, J=5.5 Hz), 4.49 (d, 2H, 5.1 Hz), 2.14 (s, 3H);

IR (KBr) 3372 (O-H stretch) cm<sup>-1</sup>;

5 MS (CI) M+1 = 358.

Analysis calculated for C<sub>14</sub>H<sub>13</sub>FINO:

C, 47.08; H, 3.67; N, 3.92.

Found: C, 47.17; H, 3.75; N, 3.72.

#### EXAMPLE 50-52

10 The following benzyl alcohols were prepared by the general procedure of Example 49.

Example No.	Compound	MP °C
50	[5-Chloro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-methanol	82-85
51	[2-(4-Iodo-2-methyl-phenylamino)-5-nitro-phenyl]-methanol	126.5-128.5
52	[5-Bromo-2-(4-iodo-2-methyl-phenylamino)-phenyl]-methanol	60.5-63.5

Several invention compounds of Formula I were prepared utilizing combinatorial synthetic techniques. The general procedure is as follows:

15 To a 0.8-mL autosampler vial in a metal block was added 40 μL of a 0.5 M solution of the acid in DMF and 40 μL of the reagent amine (2 M solution in Hunig's base and 1 M in amine in DMF). A 0.5 M solution of PyBrop was freshly prepared and 50 μL were added to the autosampler vial. The reaction was allowed to stand for 24 hours.

20 The reaction mixture was transferred to a 2-dram vial and diluted with 2 mL of ethyl acetate. The organic layer was washed with 3 mL of distilled water

and the water layer washed again with 2 mL of ethyl acetate. The combined organic layers were allowed to evaporate to dryness in an open fume hood.

5 The residue was taken up in 2 mL of 50% acetonitrile in water and injected on a semi-prep reversed phase column (10 mm × 25 cm, 5 μM spherical silica, pore size 115 Å derivatized with C-18, the sample was eluted at 4.7 mL/min with a linear ramp to 100% acetonitrile over 8.5 minutes. Elution with 100% acetonitrile continued for 8 minutes). Fractions were collected by monitoring at 214 nM. The residue was dissolved in chloroform and transferred to a preweighed vial, evaporated, and weighed again to determine the yield.

10

#### EXAMPLES 53-206

The following compounds of Formula I were prepared by combinatorial methodology:

Example No.	Compound	MS M-H
53	5-Bromo-3,4-difluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	510
54	N-(2,3-Dihydroxy-propyl)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	462
55	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperidin-1-yl-ethyl)-benzamide	577
56	3,4-Difluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	432
57	N-(2,3-Dihydroxy-propyl)-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	444
58	3,4-Difluoro-N-(3-hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	446
59	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	564
60	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyridin-4-yl-ethyl)-benzamide	571
61	4-Fluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	414

Example No.	Compound	MS M-H
62	5-Bromo-N-(3-dimethylamino-propyl)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	551
63	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide	580
64	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide	501
65	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	485
66	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyridin-4-yl-ethyl)-benzamide	493
67	N-(3-Dimethylamino-propyl)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	473
68	N-Benzyl-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	460
69	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-hydroxy-ethyl)-benzamide	384
70	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide	483
71	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-1-yl-propyl)-benzamide	495
72	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-1-yl-propyl)-benzamide	513
73	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-thiophen-2-yl-ethyl)-benzamide	480
74	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	467
75	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-morpholin-4-yl-ethyl)-benzamide	453
76	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-pyridin-4-ylmethyl-benzamide	557
77	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-pyridin-4-ylmethyl-benzamide	479
78	2-(4-Bromo-2-methyl-phenylamino)-N-(3-dimethylamino-propyl)-3,4-difluoro-benzamide	425

Example No.	Compound	MS M-H
79	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-pyridin-4-ylmethyl-benzamide	461
80	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyridin-4-yl-ethyl)-benzamide	475
81	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-pyridin-4-yl-ethyl)-benzamide	445
82	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(3-hydroxy-propyl)-benzamide	400
83	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	437
84	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-phenethyl-benzamide	474
85	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-thiophen-2-yl-ethyl)-benzamide	450
86	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-pyridin-4-ylmethyl-benzamide	431
87	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-phenethyl-benzamide	444
88	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-piperidin-1-yl-ethyl)-benzamide	451
89	5-Chloro-N-{3-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-propyl}-2-(4-iodo-2-methyl-phenylamino)-benzamide	557*
90	5-Fluoro-N-{3-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-propyl}-2-(4-iodo-2-methyl-phenylamino)-benzamide	541*
91	2-(4-Iodo-2-methyl-phenylamino)-5-nitro-N-pyridin-4-yl methyl-benzamide	487
92	5-Bromo-N-{3-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-propyl}-2-(4-iodo-2-methyl-phenylamino)-benzamide	601*
93	5-Chloro-N-(2-diethylamino-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	486*

Example No.	Compound	MS M-H
94	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperidin-1-yl-ethyl)-benzamide	497*
95	(3-Hydroxy-pyrrolidin-1-yl)-[2-(4-iodo-2-methyl-phenylamino)-5-nitro-phenyl]-methanone	466
96	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	484*
97	5-Bromo-N-(2-diethylamino-ethyl)-2-(4-iodo-2-methyl-phenylamino)- benzamide	530*
98	N-{2-[Bis-(2-hydroxy-ethyl)-amino]-ethyl}-5-chloro-2-(4-iodo-2-methyl- phenylamino)- benzamide	518*
99	N-{2-[Bis-(2-hydroxy-ethyl)-amino]-ethyl}-5-bromo-2-(4-iodo-2-methyl- phenylamino)- benzamide	562*
100	[5-Bromo-2-(4-iodo-2-methyl-phenylamino)-phenyl]-(3-hydroxy-pyrrolidin-1-yl)-methanone	499
101	2-(4-Iodo-2-methyl-phenylamino)-5-nitro-benzoic acid phenethyl ester	501
102	N-{3-[4-(2-Hydroxy-ethyl)-piperazin-1-yl]-propyl}-2-(4-iodo-2-methyl-phenylamino)- benzamide	568*
103	[5-Chloro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-(3-hydroxy-pyrrolidin-1-yl)-methanone	455
104	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-pyridin-4-ylmethyl-benzamide	460
105	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	528*
106	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperidin-1-yl-ethyl)-benzamide	542*
107	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	468*
108	5-Chloro-N-(3-dimethylamino-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	472*
109	N-{2-[Bis-(2-hydroxy-ethyl)-amino]-ethyl}-5-fluoro-2-(4-iodo-2-methyl- phenylamino)- benzamide	502*

Example No.	Compound	MS M-H
110	5-Chloro-N-(3-hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	445*
111	5-Chloro-N-(3-diethylamino-2-hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)- benzamide	516*
112	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperidin-1-yl-ethyl)-benzamide	482*
113	5-Bromo-N-(3-hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	489*
114	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-1-yl-propyl)-benzamide	556*
115	N-{2-[Bis-(2-hydroxy-ethyl)-amino]-ethyl}-2-(4-iodo-2-methyl-phenylamino)-5-nitro- benzamide	529*
116	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide	500*
117	5-Chloro-N-(3-diethylamino-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	500*
118	5-Chloro-N-(2-diisopropylamino-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	514*
119	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-1-yl-propyl)-benzamide	512*
120	2-(4-Iodo-2-methyl-phenylamino)-5-nitro-N-(2-piperidin-1-yl-ethyl)-benzamide	509*
121	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperazin-1-yl-ethyl)-benzamide	544*
122	N-(2-Diethylamino-ethyl)-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	470*
123	5-Bromo-N-(3-dimethylamino-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	516*
124	N-(3-Hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide	456*

Example No.	Compound	MS M-H
125	5-Fluoro-N-(3-hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	429*
126	N-(3-Diethylamino-propyl)-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	484*
127	N-(3-Diethylamino-propyl)-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide	511*
128	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide	544*
129	2-(4-Iodo-2-methyl-phenylamino)-5-nitro-N-(3-piperidin-1-yl-propyl)-benzamide	523*
130	[5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-(3-hydroxy-pyrrolidin-1-yl)-methanone	439
131	5-Bromo-N-(2-diisopropylamino-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	558*
132	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide	484*
133	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-1-yl-propyl)-benzamide	496*
134	[5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-methanone	482
135	N-(3-Diethylamino-2-hydroxy-propyl)-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	500*
136	[5-Chloro-2-(4-iodo-2-methyl-phenylamino)-benzoylamino]-acetic acid	443
137	2-(4-Iodo-2-methyl-phenylamino)-5-nitro-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	495*
138	N-(3-Dimethylamino-propyl)-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide	483*
139	N-(2-Diisopropylamino-ethyl)-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	498*
140	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-thiobenzoic acid S-phenethyl ester	490



Example No.	Compound	MS M-H
141	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-thiobenzoic acid S-phenethyl ester	506
142	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-thiobenzoic acid S-benzyl ester	536
143	2-(4-Iodo-2-methyl-phenylamino)-5-nitro-thiobenzoic acid S-benzyl ester	503
144	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-thiobenzoic acid S-benzyl ester	476
145	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-thiobenzoic acid S-benzyl ester	492
146	N-Cyclopropyl-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	409
147	5-Chloro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	429
148	5-Fluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	413
149	N-Benzyloxy-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	475
150	N-Benzyloxy-5-bromo-2-(4-iodo-2-methyl-phenylamino)-benzamide	593*
151	2-(4-Iodo-2-methyl-phenylamino)-5-nitro-N-(4-sulfamoyl-benzyl)-benzamide	567
152	5-Bromo-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	473
153	N-(2-Hydroxy-ethyl)-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide	521
154	N-(2-Hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide	440

Example No.	Compound	MS M-H
155	2-(4-Iodo-2-methyl-phenylamino)-N-methyl-5-nitro-N-phenyl-benzamide	486
156	5-Chloro-N-cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-benzamide	425
157	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide	459
158	N-Allyl-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	409
159	N-Benzyloxy-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide	583
160	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl-benzyl)-benzamide	538
161	N-Allyl-5-chloro-2-(4-iodo-2-methyl-phenylamino)-benzamide	425
162	N-Cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide	436
163	5-Bromo-N-cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-benzamide	469
164	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide	475
165	5-Iodo-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl-benzyl)-benzamide	646
166	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl-benzyl)-benzamide	598
167	N-Allyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide	436

Example No.	Compound	MS M-H
168	2-(4-Iodo-2-methyl-phenylamino)-5-nitro-N-(4-sulfamoyl-benzyl)-benzamide	565
169	N-Allyl-5-bromo-2-(4-iodo-2-methyl-phenylamino)-benzamide	469
170	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-benzamide	473
171	N-Cyclopropyl-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide	517
172	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide	519
173	N-Benzyloxy-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide	502
174	N-Cyclohexyl-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide	559
175	N-Allyl-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide	517
176	5-Iodo-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-benzamide	581
177	2-(4-Iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-5-nitro-benzamide	500
178	5-Iodo-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide	567
179	N-Cyclohexyl-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	451
180	5-Chloro-N-cyclohexyl-2-(4-iodo-2-methyl-phenylamino)-benzamide	467
181	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-benzamide	533
182	5-Bromo-N-cyclohexyl-2-(4-iodo-2-methyl-phenylamino)-benzamide	511
183	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-benzamide	489

Example No.	Compound	MS M-H
184	N-Cyclohexyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro- benzamide	478
185	N-Benzyloxy-5-bromo-2-(4-iodo-2-methyl-phenylamino)- benzamine	538
186	N-Benzyloxy-5-fluoro-2-(4-iodo-2-methyl-phenylamino)- benzamide	477
187	5-Chloro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)- benzamide	431
188	5-Bromo-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)- benzamide	475
189	2-(4-Iodo-2-methyl-phenylamino)-N-methyl-5-nitro-N-phenyl- benzamide	488
190	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl- benzamide	477
191	N-(2-Hydroxy-ethyl)-5-iodo-2-(4-iodo-2-methyl-phenylamino)- benzamide	523
192	5-Chloro-N-cyclopropyl-2-(4-iodo-2-methyl-phenylamino)- benzamide	425
193	N-Allyl-5-chloro-2-(4-iodo-2-methyl-phenylamino)-benzamide	427
194	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl- benzamide	461
195	N-(2-Hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-5-nitro- benzamide	442
196	5-Fluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)- benzamide	415
197	5-Bromo-N-cyclopropyl-2-(4-iodo-2-methyl-phenylamino)- benzamide	472
198	N-Cyclopropyl-5-fluoro-2-(4-iodo-2-methyl-phenylamino)- benzamide	411
199	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl- benzyl)-benzamide	540

Example No.	Compound	MS M-H
200	N-Cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide	438
201	N-Allyl-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	411
202	N-Benzyloxy-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide	585
203	N-Allyl-5-bromo-2-(4-iodo-2-methyl-phenylamino)-benzamide	472
204	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl-benzyl)-benzamide	601
205	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide	522
206	N-Allyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide	438

\* M+H

#### EXAMPLE 207

##### Preparation of [4-Chloro-2-(1H-tetrazol-5-yl)-(4-iodo-2-methyl-phenyl)-amine

##### Step a: Preparation of 5-chloro-2-fluoro-benzaldehyde

5 To a solution of 1-chloro-4-fluorobenzene (13.06 g, 0.1 mol) in THF (180 mL), at -78°C, LDA (2M solution in THF, 50 mL, 0.1 mol) was added drop wise. After stirring at -78°C for 1.5 hours, DMF (8 mL) was added to the reaction mixture and allowed to warm up to room temperature overnight. The reaction mixture was partitioned between water and Et<sub>2</sub>O. The Et<sub>2</sub>O layer was dried

10 (MgSO<sub>4</sub>) and the solvent removed in vacuum to give 14.95 g (94%) yield of crude aldehyde: <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ, 10.3 (s, -C(=O)H).

##### Step b: Preparation of 5-chloro-2-fluoro-benzaldehyde oxime

A solution of 5-chloro-2-fluoro-benzaldehyde (10 g, 0.0631 mol), hydroxylamine hydrochloride (6.57 g, 0.0946 mol) and pyridine (8.3 mL,

15 0.1010 mol) in EtOH (100 mL) was heated at 75°C (oil bath temperature) for 1 hour and the solvent removed under vacuum to give an oil. The oil was

partitioned between water and CH<sub>2</sub>Cl<sub>2</sub>. The CH<sub>2</sub>Cl<sub>2</sub> layer was dried (MgSO<sub>4</sub>) and the solvent removed under vacuum to give crude aldoxime as a solid. The solid was purified by medium pressure liquid chromatography on silica. Elution with CH<sub>2</sub>Cl<sub>2</sub> gave 4.87 g (28%) of the aldoxime as white solid: mp 95-97°C;

5 Analysis calculated for C<sub>7</sub>H<sub>5</sub>NOFCl:

C, 48.44; H, 2.90; N, 8.07.

Found: C, 48.55; H, 2.69, N, 7.90.

Step c: Preparation of 5-chloro-2-fluoro-benzonitrile

10 A solution of the 5-chloro-2-fluoro-benzaldehyde oxime (3.15 g, 0.0182 mol) in acetic anhydride (150 mL) was refluxed for 16 hours. The reaction mixture was cooled to room temperature and poured into saturated aqueous NaHCO<sub>3</sub> (200 mL) solution. The mixture was extracted with Et<sub>2</sub>O. The Et<sub>2</sub>O layer was dried (K<sub>2</sub>CO<sub>3</sub>) and the solvent removed to give the product as an oily solid. The product was used without further purification in the next step.

15 Step d: Preparation of 5-(5-chloro-2-fluoro-phenyl)-1H-tetrazole

A mixture of 5-chloro-2-fluoro-benzonitrile (2.84 g, 0.01823 mol), butanol (15 mL), sodium azide (1.543 g, 0.0237 mol), acetic acid (1.36 mL, 0.0237 mol) was refluxed for 24 hours. The reaction mixture was cooled to room temperature, additional 1.543 g sodium azide added, and the reaction mixture refluxed for 20 additional 24 hours. After cooling to room temperature, Et<sub>2</sub>O (100 mL) and 10% aqueous NaOH (200 mL) were added sequentially. The mixture was vigorously stirred. The aqueous layer was separated, cooled with ice-methanol bath (-15°C) and acidified to pH 1 with conc. HCl. A gray solid precipitated. The solid was dried in vacuum at 50°C to give 1.76 g (49%) of 5-(5-chloro-2-fluoro-phenyl)-1H-tetrazole: mp partial melt at 110°C, complete melting at 124°C); 25  
<sup>1</sup>H (400 Mz, CDCl<sub>3</sub>): δ 8.19-8.08 (m, 1H), 7.77-7.71 (m, 1H), 7.61-7.52 (m, 1H);  
<sup>13</sup>C (100 Mz, CDCl<sub>3</sub>): δ 159.00, 156.49, 140.88, 133.02, 132.93, 130.73, 129.23, 129.21, 129.08, 126.05, 118.96, 118.73, 114.50;

MS (CI) M+1 = 199 (100), M = 198 (6).

Step e: Preparation of [4-Chloro-2-(1H-tetrazol-5-yl)-(4-iodo-2-methyl-phenyl)]-amine

To a solution of 2-methyl-4-iodoaniline (3.52 g, 0.0151 mol) in THF (25 mL) at -78°C, LDA (2 molar solution in THF, 11.33 mL, 0.02267 mol) was added dropwise. After stirring for 0.5 hours, a solution of 1-(tetrazol-5-yl)-2-fluoro-5-chlorobenzene (1.5 g, 0.00756 mol) in THF (15 mL) was added dropwise. The reaction was stirred for 16 hours as it warmed up to room temperature. The reaction mixture was quenched with aqueous conc. NH<sub>4</sub>Cl solution and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was dried (MgSO<sub>4</sub>) and the solvent removed giving a crude product as an oil. The oil with CH<sub>2</sub>Cl<sub>2</sub>:>CH<sub>2</sub>Cl<sub>2</sub>:MeOH (9.7:0.3) gave 1.5 g (48%) of the desired product:

mp 205-208°C; <sup>1</sup>H (400 Mz, DMSO): δ 9.13 (s, 1H), 8.00-7.99 (s, 1H), 7.69 (s, 1H), 7.55-7.52 (m, 1H), 7.43-7.40 (m, 1H), 7.12-7.05 (m, 1H), 2.24 (s, 3H); <sup>13</sup>C (100 Mz, CDCl<sub>3</sub>): δ 141.87, 139.28, 138.88, 135.47, 133.71, 131.65, 128.15, 123.69, 121.94, 116.68, 87.79, 17.22; MS (CI) M+2 = 413 (44), M+1 = 412 (85), M = 411 (100).

Analysis calculated for C<sub>14</sub>H<sub>11</sub>N<sub>5</sub>ClI·0.5H<sub>2</sub>O:

C, 39.97; H, 2.87; N, 16.65.

Found: C, 38.87, H, 2.77; N, 16.47.

The following tetrazole substituted phenylamines were prepared by following the general procedure of Example 207.

EXAMPLE 208

(4-iodo-2-methyl-phenyl)-[2-(1H-tetrazol-5-yl)-phenyl]amine, mp 231°C

(dec)

### EXAMPLE 209


[4-nitro-2-(1H-tetrazol-5-yl)-(4-iodo-2-methyl-phenyl)-amine, mp 205-208°C.]

The 4-bromo and 4-iodo phenylamino benzhydroxamic acid derivatives of Formula II can be prepared from commercially available starting materials utilizing synthetic methodologies well-known to those skilled in organic chemistry. A typical synthesis is carried out by reacting a 4-bromo or 4-iodo aniline with a benzoic acid having a leaving group at the 2-position to give a phenylamino benzoic acid, and then reacting the benzoic acid phenylamino derivative with a hydroxylamine derivative (Scheme 3), where L is a leaving group, for example halo such as fluoro, chloro, bromo or iodo, or an activated hydroxy group such as a diethylphosphate, trimethylsilyloxy, p-nitrophenoxy, or phenylsulfonyloxy.

The reaction of aniline and the benzoic acid derivative generally is accomplished by mixing the benzoic acid with an equimolar quantity or excess of the aniline in an unreactive organic solvent such as tetrahydrofuran, or toluene, in the presence of a base such as lithium diisopropylamide, n-butyl lithium, sodium hydride, and sodium amide. The reaction generally is carried out at a temperature of about -78°C to about 25°C, and normally is complete within about 2 hours to about 4 days. The product can be isolated by removing the solvent, for example by evaporation under reduced pressure, and further purified, if desired, by standard methods such as chromatography, crystallization, or distillation.



Scheme 3




The phenylamino benzoic acid next is reacted with a hydroxylamine derivative HNR<sub>6a</sub>OR<sub>7a</sub> in the presence of a peptide coupling reagent.

- 5 Hydroxylamine derivatives that can be employed include methoxylamine, N-ethyl-isopropoxy amine, and tetrahydro-oxazine. Typical coupling reagents include 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ), 1,3-dicyclohexylcarbodiimide (DCC), bromo-tris(pyrrolidino)-phosphonium hexafluorophosphate (PyBrOP) and (benzotriazolyloxy)tripyrrolidino

phosphonium hexafluorophosphate (PyBOP). The phenylamino benzoic acid and hydroxylamino derivative normally are mixed in approximately equimolar quantities in an unreactive organic solvent such as dichloromethane, tetrahydrofuran, chloroform, or xylene, and an equimolar quantity of the coupling reagent is added. A base such as triethylamine or diisopropylethylamine can be added to act as an acid scavenger if desired. The coupling reaction generally is complete after about 10 minutes to 2 hours, and the product is readily isolated by removing the reaction solvent, for instance by evaporation under reduced pressure, and purifying the product by standard methods such as chromatography or crystallizations from solvents such as acetone, diethyl ether, or ethanol.


An alternative method for making the invention compounds involves first converting a benzoic acid to a hydroxamic acid derivative, and then reacting the hydroxamic acid derivative with an aniline. This synthetic sequence is depicted in Scheme 4, where L is a leaving group. The general reaction conditions for both of the steps in Scheme 4 are the same as those described above for Scheme 3.

Scheme 4



Yet another method for making invention compounds comprises reacting a phenylamino benzhydroxamic acid with an ester forming group as depicted in Scheme 5, where L is a leaving group such as halo, and a base is triethylamine or diisopropylamine.

Scheme 5



The synthesis of compounds of Formula (II) is further illustrated by the following detailed examples.

5

#### EXAMPLE 1a

##### 4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide

##### (a) Preparation of 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid

To a stirred solution containing 3.16 g (0.0133 mol) of 2-amino-5-iodotoluene in 5 mL of tetrahydrofuran at  $-78^{\circ}\text{C}$  was added 10 mL (0.020 mol) of a 2.0 M lithium diisopropylamide in tetrahydrofuran/heptane/ethylbenzene (Aldrich) solution. The resulting green suspension was stirred vigorously for 15 minutes, after which time a solution of 1.00 g (0.00632 mol) of 2,4-difluorobenzoic acid in 10 mL of tetrahydrofuran was added. The reaction temperature was allowed to increase slowly to room temperature, at which temperature the mixture was stirred for 2 days. The reaction mixture was concentrated by evaporation of the solvent under reduced pressure. Aqueous HCl

(10%) was added to the concentrate, and the solution was extracted with dichloromethane. The organic phase was dried ( $\text{MgSO}_4$ ) and then concentrated over a steambath to low volume (10 mL) and cooled to room temperature. The off-white fibers which formed were collected by vacuum filtration, rinsed with hexane, and dried in a vacuum-oven ( $76^\circ\text{C}$ ; ca. 10 mm of Hg) to afford 1.10 g (47%) of the desired material; mp  $224\text{--}229.5^\circ\text{C}$ ;

$^1\text{H}$  NMR (400 MHz, DMSO):  $\delta$  9.72 (s, 1H), 7.97 (dd, 1H,  $J=7.0, 8.7$  Hz), 7.70 (d, 1H,  $J=1.5$  Hz), 7.57 (dd, 1H,  $J=8.4, 1.9$  Hz), 7.17 (d, 1H,  $J=8.2$  Hz), 6.61–6.53 (m, 2H), 2.18 (s, 3H);

$^{13}\text{C}$  NMR (100 MHz, DMSO):  $\delta$  169.87, 166.36 (d,  $J_{\text{C-F}}=249.4$  Hz), 150.11 (d,  $J_{\text{C-F}}=11.4$  Hz), 139.83, 138.49, 136.07, 135.26 (d,  $J_{\text{C-F}}=11.5$  Hz), 135.07, 125.60, 109.32, 104.98 (d,  $J_{\text{C-F}}=21.1$  Hz), 99.54 (d,  $J_{\text{C-F}}=26.0$  Hz), 89.43, 17.52;

$^{19}\text{F}$  NMR (376 MHz, DMSO):  $\delta$  -104.00 to -104.07 (m);

IR (KBr)  $1670$  ( $\text{C=O}$  stretch) $\text{cm}^{-1}$ ;

MS (CI)  $M+1 = 372$ .

Analysis calculated for  $\text{C}_{14}\text{H}_{11}\text{FINO}_2$ :

C, 45.31; H, 2.99; N, 3.77.

Found: C, 45.21; H, 2.77; N, 3.64.

(b) Preparation of 4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide

To a stirred solution of 4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid (0.6495 g, 0.001750 mol), O-(tetrahydro-2H-pyran-2-yl)-hydroxylamine (0.2590 g, 0.002211 mol), and diisopropylethylamine (0.40 mL, 0.0023 mol) in 31 mL of an equivolume tetrahydrofuran-dichloromethane solution was added 1.18 g (0.00227 mol) of solid PyBOP ([benzotriazolyl]oxy)tripyrrolidino phosphonium hexafluorophosphate, Advanced ChemTech) directly. The reaction mixture was stirred for 30 minutes after which time it was concentrated in vacuo. The brown oil was treated with 10% aqueous hydrochloric acid. The suspension was extracted with ether. The organic extraction was washed with 10% sodium

hydroxide followed by another 10% hydrochloric acid wash, was dried (MgSO<sub>4</sub>) and concentrated in vacuo to afford 1.0 g of a light-brown foam. This intermediate was dissolved in 25 mL of ethanolic hydrogen chloride, and the solution was allowed to stand at room temperature for 15 minutes. The reaction mixture was concentrated in vacuo to a brown oil that was purified by flash silica chromatography. Elution with a gradient (100 % dichloromethane to 0.6 % methanol in dichloromethane) afforded 0.2284 g of a light-brown viscous oil. Scratching with pentane-hexanes and drying under high vacuum afforded 0.1541 g (23%) of an off-white foam; mp 61-75°C;

<sup>1</sup>H NMR (400 MHz, DMSO): δ 11.34 (s, 1H), 9.68 (s, 1H), 9.18 (s, 1H), 7.65 (d, 1H, J=1.5 Hz), 7.58 (dd, 1H, J=8.7, 6.8 Hz), 7.52 (dd, 1H, J=8.4, 1.9 Hz), 7.15 (d, 1H, J=8.4 Hz), 6.74 (dd, 1H, J=11.8, 2.4 Hz), 6.62 (ddd, 1H, J=8.4, 8.4, 2.7 Hz), 2.18 (s, 3H);

<sup>13</sup>C NMR (100 MHz, DMSO): δ 165.91, 164.36 (d, J<sub>C-F</sub>=247.1 Hz), 146.78, 139.18, 138.77, 135.43, 132.64, 130.60 (d, J<sub>C-F</sub>=11.5 Hz), 122.23, 112.52, 104.72 (d, J=22.1 Hz), 100.45 (d, J<sub>C-F</sub>=25.2 Hz), 86.77, 17.03;

<sup>19</sup>F NMR (376 MHz, DMSO): δ -107.20 to -107.27 (m);

IR (KBr) 3307 (broad, O-H stretch), 1636 (C=O stretch) cm<sup>-1</sup>;

MS (CI) M+1 = 387.

Analysis calculated for C<sub>14</sub>H<sub>12</sub>FIN<sub>2</sub>O<sub>2</sub>:

C, 43.54; H, 3.13; N, 7.25.

Found: C, 43.62; H, 3.24; N, 6.98.

## EXAMPLE 2a

### 5-Bromo-3,4-difluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide

#### (a) Preparation of 5-Bromo-2,3,4-trifluorobenzoic acid

To a stirred solution comprised of 1-bromo-2,3,4-trifluorobenzene (Aldrich, 99%; 5.30 g, 0.0249 mol) in 95 mL of anhydrous tetrahydrofuran cooled to -78°C was slowly added 12.5 mL of 2.0 M lithium diisopropylamide in heptane/tetrahydrofuran/ethylbenzene solution (Aldrich). The mixture was stirred

for 1 hour and transferred by canula into 700 mL of a stirred saturated ethereal carbon dioxide solution cooled to  $-78^{\circ}\text{C}$ . The cold bath was removed, and the reaction mixture was stirred for 18 hours at ambient temperature. Dilute (10%) aqueous hydrochloric acid (ca. 500 mL) was poured into the reaction mixture, and the mixture was subsequently concentrated on a rotary evaporator to a crude solid. The solid product was partitioned between diethyl ether (150 mL) and aq. HCl (330 mL, pH 0). The aqueous phase was extracted with a second portion (100 mL) of diethyl ether, and the combined ethereal extracts were washed with 5% aqueous sodium hydroxide (200 mL) and water (100 mL, pH 12). These combined alkaline aqueous extractions were acidified to pH 0 with concentrated aqueous hydrochloric acid. The resulting suspension was extracted with ether ( $2 \times$  200 mL). The combined organic extracts were dried ( $\text{MgSO}_4$ ), concentrated in vacuo, and subjected to high vacuum until constant mass was achieved to afford 5.60 g (88% yield) of an off-white powder; mp  $139\text{--}142.5^{\circ}\text{C}$ ;

$^1\text{H}$  NMR (400 MHz, DMSO):  $\delta$  13.97 (broad s, 1H, 8.00–7.96 (m, 1H);

$^{13}\text{C}$  NMR (100 MHz, DMSO):  $\delta$  162.96, 129.34, 118.47, 104.54 (d,  $J_{\text{C-F}}=22.9$  Hz);

$^{19}\text{F}$  NMR (376 MHz, DMSO):  $\delta$  -120.20 to -120.31 (m), -131.75 to -131.86 (m), -154.95 to -155.07 (m);

IR (KBr) 1696 ( $\text{C}=\text{O}$  stretch) $\text{cm}^{-1}$ ;

MS (CI)  $M+1 = 255$ .

Analysis calculated for  $\text{C}_{74}\text{H}_{21}\text{BrF}_3\text{O}_2$ :

C, 32.97; H, 0.79; N, 0.00; Br, 31.34; F, 22.35.

Found: C, 33.18; H, 0.64; N, 0.01; Br, 30.14; F, 22.75.

(b) Preparation of 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid

To a stirred solution comprised of 1.88 g (0.00791 mol) of 2-amino-5-iodotoluene in 10 mL of tetrahydrofuran at  $-78^{\circ}\text{C}$  was added 6 mL (0.012 mol) of a 2.0 M lithium diisopropylamide in tetrahydrofuran/heptane/ethylbenzene (Aldrich) solution. The resulting green suspension was stirred vigorously for

10 minutes, after which time a solution of 1.00 g (0.00392 mol) of 5-bromo-2,3,4-trifluorobenzoic acid in 15 mL of tetrahydrofuran was added. The cold bath was subsequently removed, and the reaction mixture stirred for 18 hours. The mixture was concentrated, and the concentrate was treated with 100 mL of dilute  
5 (10%) aqueous hydrochloric acid. The resulting suspension was extracted with ether (2 × 150 mL), and the combined organic extractions were dried (MgSO<sub>4</sub>) and concentrated in vacuo to give an orange solid. The solid was triturated with boiling dichloromethane, cooled to ambient temperature, and collected by filtration. The solid was rinsed with dichloromethane, and dried in the vacuum-  
10 oven (80°C) to afford 1.39 g (76%) of a yellow-green powder; mp 259.5-262°C; <sup>1</sup>H NMR (400 MHz, DMSO): δ 9.03 (s, 1H), 7.99 (dd, 1H, J=7.5, 1.9 Hz), 7.57 (dd, 1H, J=1.5 Hz), 7.42 (dd, 1H, J=8.4, 1.9 Hz), 6.70 (dd, 1H, J=8.4, 6.0 Hz), 2.24 (s, 3H);  
<sup>19</sup>F NMR (376 MHz, DMSO): δ -123.40 to -123.47 (m); -139.00 to -139.14 (m);  
15 IR (KBr) 1667 (C=O stretch)cm<sup>-1</sup>;  
MS (CI) M+1 = 469.

Analysis calculated for C<sub>14</sub>H<sub>9</sub>BrF<sub>2</sub>INO<sub>2</sub>:

C, 35.93; H, 1.94; N, 2.99; Br, 17.07; F, 8.12; I, 27.11.

Found: C, 36.15; H, 1.91; N, 2.70; Br, 16.40; F, 8.46; I, 26.05.

20 (c) Preparation of 5-Bromo-3,4-difluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide

To a stirred solution comprised of 5-bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid (0.51 g, 0.0011 mol), O-(tetrahydro-2H-pyran-2-yl)-hydroxylamine (0.15 g, 0.0013 mol), and diisopropylethylamine  
25 (0.25 mL, 0.0014 mol) in 20 mL of an equivolume tetrahydrofuran-dichloromethane solution was added 0.6794 g (0.001306 mol) of solid PyBOP (Advanced ChemTech) directly. The reaction mixture was stirred at 24°C for 10 minutes, and then was concentrated to dryness in vacuo. The concentrate was suspended in 100 mL of 10% aqueous hydrochloric acid. The suspension was  
30 extracted with 125 mL of diethyl ether. The ether layer was separated, washed with 75 mL of 10% aqueous sodium hydroxide, and then with 100 mL of dilute



acid. The ether solution was dried ( $\text{MgSO}_4$ ) and concentrated in vacuo to afford 0.62 g (100%) of an off-white foam. The foam was dissolved in ca. 15 mL of methanolic hydrogen chloride. After 5 minutes, the solution was concentrated in vacuo to an oil, and the oil was purified by flash silica chromatography. Elution with dichloromethane: dichloromethane-methanol (99:1) afforded 0.2233 g (42%) of a yellow powder. The powder was dissolved in diethyl ether and washed with dilute hydrochloric acid. The organic phase was dried ( $\text{MgSO}_4$ ) and concentrated in vacuo to afford 0.200 g of a foam. This product was triturated with pentane to afford 0.1525 g of a powder that was repurified by flash silica chromatography. Elution with dichloromethane afforded 0.0783 g (15%) of an analytically pure title compound, mp 80-90°C;

$^1\text{H}$  NMR (400 MHz, DMSO):  $\delta$  11.53 (s, 1H), 9.38 (s, 1H), 8.82 (s, 1H), 7.70 (dd, 1H,  $J=7.0, 1.9$  Hz), 7.53 (s, 1H), 7.37 (dd, 1H,  $J=8.4, 1.9$  Hz), 6.55 (dd, 1H,  $J=8.2, 6.5$  Hz), 2.22 (s, 3H);

$^{19}\text{F}$  NMR (376 MHz, DMSO):  $\delta$  -126.24 to -126.29 (m), -137.71 to -137.77 (m);

IR (KBr) 3346 (broad, O-H stretch), 1651 (C=O stretch) $\text{cm}^{-1}$ ;

MS (CI)  $M+1 = 484$ .

Analysis calculated for  $\text{C}_{14}\text{H}_{10}\text{BrF}_2\text{IN}_2\text{O}_2$ :

C, 34.81; H, 2.09; N, 5.80.

Found: C, 34.53; H, 1.73; N, 5.52.

Examples 3a to 12a in the table below were prepared by the general procedure of Examples 1a and 2a.

#### EXAMPLES 13a-77a

Examples 13a to 77a were prepared utilizing combinatorial synthetic methodology by reacting appropriately substituted phenylamino benzoic acids

(e.g., as shown in Scheme 1) and hydroxylamines (e.g.,  $(\text{NHR}_{6a})\text{-O-R}_{7a}$ ). A general method is given below:

To a 0.8-mL autosampler vial in a metal block was added 40  $\mu$ L of a 0.5 M solution of the acid in DMF and 40  $\mu$ L of the hydroxylamine (2 M solution in Hunig's base and 1 M in amine in DMF). A 0.5 M solution of PyBrOP was freshly prepared, and 50  $\mu$ L were added to the autosampler vial. The reaction was allowed to stand for 24 hours.

The reaction mixture was transferred to a 2-dram vial and diluted with 2 mL of ethyl acetate. The organic layer was washed with 3 mL of distilled water and the water layer washed again with 2 mL of ethyl acetate. The combined organic layers were allowed to evaporate to dryness in an open fume hood.

The residue was taken up in 2 mL of 50% acetonitrile in water and injected on a semi-prep reversed phase column (10 mm  $\times$  25 cm, 5  $\mu$ M spherical silica, pore Size 115 A derivatized with C-18, the sample was eluted at 4.7 mL/min with a linear ramp to 100% acetonitrile over 8.5 minutes. Elution with 100% acetonitrile continued for 8 minutes.) Fractions were collected by monitoring at 214 nm. The desired fractions were evaporated using a Zymark Turbovap. The product was dissolved in chloroform and transferred to a preweighed vial, evaporated, and weighed again to determine the yield. The structure was confirmed by mass spectroscopy.

EXAMPLES 3a-77a

Example No.	Compound	Melting Point (°C)	MS (M-H <sup>+</sup> )
3a	2-(4-bromo-2-methyl-phenylamino)-4-fluoro-N-hydroxy-benzamide	56-75 dec	523
4a	5-Chloro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide	65 dec	
5a	5-Chloro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-N-methyl-benzamide	62-67	
6a	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(terahydropyran-2-yloxy)benzamide	105-108	
7a	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-methoxybenzamide	64-68	
8a	4-Fluoro-N-hydroxy-2-(4-fluoro-2-methyl-phenylamino)-benzamide	119-135	
9a	4-Fluoro-N-hydroxy-2-(2-methyl phenylamino)-benzamide	101-103	
10a	4-Fluoro-2-(4-fluor-2-methyl-phenylamino)-N-(terahydropyran-2-yloxy)benzamide	142-146	
11a	4-Fluoro-N-hydroxy-2-(4-cluoro-2-methyl-phenylamino)-benzamide	133.5-135	

Example No.	Compound	Melting Point (°C)	MS (M-H <sup>+</sup> )
12a	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-phenylmethoxy-benzamide	107-109.5	
13a	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-methoxy-benzamide		399
14a	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-methoxy-benzamide		417
15a	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-methoxy-benzamide		369
16a	2-(4-Bromo-2-methyl-phenylamino)-N-ethoxy-3,4-difluoro-benzamide		342* (M-EtO)
17a	5-Bromo-N-ethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		509
18a	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-isopropoxy-benzamide		445
19a	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-isopropoxy-benzamide		397
20a	4-Fluoro-N-(furan-3-ylmethoxy)-2-(4-iodo-2-methyl-phenylamino)-benzamide		465

Example No.	Compound	Melting Point (°C)	MS
21a	3,4-Difluoro-N-(furan-3-ylmethoxy)-2-(4-iodo-2-methyl-phenylamino)-benzamide		483
22a	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(furan-3-ylmethoxy)-benzamide		435
23a	5-Bromo-3,4-difluoro-N-(furan-3-ylmethoxy)-2-(4-iodo-2-methyl-phenylamino)-benzamide		561
24a	5-Bromo-N-(but-2-enyloxy)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		536
25a	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(prop-2-ynyloxy)-benzamide		423
26a	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(prop-2-ynyloxy)-benzamide		441
27a	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(1-methyl-prop-2-ynyloxy)-benzamide		455
28a	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(1-methyl-prop-2-ynyloxy)-benzamide		407
29a	N-(But-3-ynyloxy)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		455

Example No.	Compound	Melting Point (°C)	MS
30a	2-(4-Bromo-2-methyl-phenylamino)-N-(but-3-ynyloxy)-3,4-difluoro-benzamide		407
31a	5-Bromo-N-(but-3-ynyloxy)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		533
32a	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-phenyl-prop-2-ynyloxy)-benzamide		517
33a	3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(3-phenyl-prop-2-ynyloxy)-benzamide		469
34a	3,4-Difluoro-N-[3-(3-fluoro-phenyl)-prop-2-ynyloxy]-2-(4-iodo-2-methyl-phenylamino)-benzamide		535
35a	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-[3-(3-fluoro-phenyl)-prop-2-ynyloxy]-benzamide		487
36a	3,4-Difluoro-N-[3-(2-fluoro-phenyl)-prop-2-ynyloxy]-2-(4-iodo-2-methyl-phenylamino)-benzamide		535
37a	5-Bromo-3,4-difluoro-N-[3-(2-fluoro-phenyl)-prop-2-ynyloxy]-2-(4-iodo-2-methyl-phenylamino)-benzamide		613

Example No.	Compound	Melting Point (°C)	MS (M-H <sup>+</sup> )
38a	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-5-phenyl-pent-2-en-4-ynyloxy)-benzamide		557* *(M+H)
39a	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(3-methyl-5-phenyl-pent-2-en-4-ynyloxy)-benzamide		510
40a	N-Ethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		431
41a	2-(4-Bromo-2-methyl-phenylamino)-N-ethoxy-3,4-difluoro-benzamide		383
42a	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-propoxy-benzamide		427
43a	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-propoxy-benzamide		445
44a	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-propoxy-benzamide		397
45a	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-propoxy-benzamide		523
46a	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-isopropoxy-benzamide		427

Example No.	Compound	Melting Point (°C)	MS (M-H <sup>+</sup> )
47a	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-isopropoxy-benzamide		445
48a	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-isopropoxy-benzamide		397
49a	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-isopropoxy-benzamide		523
50a	N-Cyclobutyloxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		457
51a	2-(4-Bromo-2-methyl-phenylamino)-N-cyclobutyloxy-3,4-difluoro-benzamide		409
52a	N-Cyclopentyloxy-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		453
53a	N-Cyclopentyloxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		471
54a	2-(4-Bromo-2-methyl-phenylamino)-N-cyclopentyloxy-3,4-difluoro-benzamide		423
55a	N-Cyclopropylmethoxy-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		439
56a	N-Cyclopropylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		457



Example No.	Compound	Melting Point (°C)	MS (M-H <sup>+</sup> )
57a	2-(4-Bromo-2-methyl-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide		409
58a	5-Bromo-N-cyclopropylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)		435
59a	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-phenoxy-ethoxy)-benzamide		505
60a	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-phenoxy-ethoxy)-benzamide		523
61a	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-phenoxy-ethoxy)-benzamide		475
62a	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(thiophen-2-ylmethoxy)-benzamide		481
63a	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(thiophen-2-ylmethoxy)-benzamide		499
64a	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(thiophen-2-ylmethoxy)-benzamide		451
65a	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-methyl-allyloxy)-benzamide		439

Example No.	Compound	Melting Point (°C)	MS (M-H <sup>+</sup> )
66a	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-methyl-allyloxy)-benzamide		457
67a	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-methyl-allyloxy)-benzamide		410
68a	N-(But-2-enyloxy)-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		439
69a	N-(But-2-enyloxy)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		457
70a	2-(4-Bromo-2-methyl-phenylamino)-N-(but-2-enyloxy)-3,4-difluoro-benzamide		410
71a	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(prop-2-ynyloxy)-benzamide		441
72a	N-(But-3-ynyloxy)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		455
73a	2-(4-Bromo-2-methyl-phenylamino)-N-(4,4-dimethyl-pent-2-ynyloxy)-3,4-difluoro-benzamide		449
74a	N-(But-2-enyloxy)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		457

Example No.	Compound	Melting Point (°C)	MS (M-H <sup>+</sup> )
75a	2-(4-Bromo-2-methyl-phenylamino)-N-(but-2-enyloxy)-3,4-difluoro-benzamide		410
76a	N-(3-tert-butyl-propyn-2-yl)oxy-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		479
77a	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-phenylmethoxy-benzamide		577* *CI

#### D. Pharmacological Activity

The anticancer activity of the combinations provided by this invention has been evaluated in standard assays designed to measure anticancer utility. In a typical cell culture assay using colon 26 carcinoma cells, paclitaxel in combination with a MEK inhibitor proved to be more efficacious than either agent alone, thus establishing a surprising synergistic effect. The colon 26 carcinoma cells were originally collected from a mouse that had undergone surgery to remove the infected section of the colon, and are now readily available from Southern Research Institute (Birmingham, Alabama, USA). The cells were cultured to approximately 80% confluency on Day 0 of the assay. At 72 hours after the 80% confluency was established, dimethylsulfoxide (DMSO) was added to one set of cells to act as untreated controls. Paclitaxel at concentrations of 30 nM and 100 nM was added to other sets of cells. All of the cells were incubated at 38°C for 48 hours, at which time MEK inhibitor 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide (PD184352), at a concentration of 1.0 micromolar, was added to one set of the DMSO control cells, and to the cells containing the two concentrations of paclitaxel. All cells were again incubated for an additional 48-hour period. The cells were harvested from the growth medium, and were fixed in ethanol. The cells were then treated with FITC (fluorescein

isothiocyanate)-labeled phalloidin (Sigma). Binding of phalloidin-FITC to depolymerized actin thereby serves as a measure of apoptosis. Propidium iodide was also added to the treated and control cells for the purpose of staining all cells. The extent of apoptosis of tumor cells was measured by flow cytometry analysis.

Figure 1 shows the results of the foregoing assay. The data establish that the vehicle alone (DMSO) caused no effect on apoptosis (programmed cell death) of the colon 26 carcinoma cells. The MEK inhibitor caused about 5% increase of apoptosis at 30 nM, and paclitaxel caused about 18% increase at 100 nM, and about 9% increase at 30 nM. Surprisingly, the combination of MEK inhibitor and paclitaxel (at 100 nM) caused a dramatic 44% incidence in the programmed cell death of the carcinoma cells. At the 30 nM concentration of paclitaxel, the combination caused about an 18 % incidence in apoptosis. These results establish the combination of MEK inhibitors and paclitaxel provided by this invention is surprisingly effective at killing cancer cells, and accordingly is useful to treat patients suffering from cancer and in need of treatment.

The assay described above was repeated, and the results (see Figure 2) confirmed that the combinations of this invention are useful to treat and control cancer. In this second study, DMSO did cause measurable cell death, somewhat similar to that observed with the 30 nM concentration of paclitaxel alone. The MEK inhibitor 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide caused about an 18% incidence in apoptosis when administered alone, and paclitaxel caused only about an 11% incidence when administered at 100 nM alone. As in the assay results discussed above, the combination of MEK inhibitor and paclitaxel caused a dramatic and unexpected increase in cancer cell death. These results further establish the antitumor activity of the combinations provided by this invention.

Another cell culture assay was carried out using HT-29 colon carcinoma cells. Paclitaxel and 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide were evaluated for their effect on apoptosis alone and in combination (see Figure 3). Again, the combination of mitotic agent and selective MEK inhibitor proved to be more efficacious than using either agent alone.

Further support for the claims of the present invention was provided by the use of non-small cell lung carcinoma cells (A549) in culture using the protocol used previously for the colon cell lines. In this case, only one set of experiments was performed and repetition is planned. The tumor line treated with Taxol alone showed a much higher incidence of apoptosis than the colon lines (41% at 10 nM Taxol). Ten nanomolar Taxol with 1 micromolar PD 184352 gave a 47% incidence in apoptosis (6% increase). The A549 cells appear to be quite sensitive to Taxol alone.